Publikationen

1. Stenzinger A, Edsjö A, Ploeger C, Friedman M, Fröhling S, Wirta V, Seufferlein T, Botling J, Duyster J, Akhras M, Thimme R, Fioretos T, Bitzer M, Cavelier L, Schirmacher P, Malek N, Rosenquist R. Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Semin Cancer Biol. 2022 Sep;84:242-254. doi: 10.1016/j.semcancer.2021.05.026. Epub 2021 May 24. Review. PubMed PMID: 34033893.

2. Rosenquist R, Fröhling S, Stamatopoulos K. Precision medicine in cancer: A paradigm shift. Semin Cancer Biol. 2022 Sep;84:1-2. doi: 10.1016/j.semcancer.2022.05.008. Epub 2022 May 18. PubMed PMID: 35597437.

3. van der Graaf WTA, Tesselaar MET, McVeigh TP, Oyen WJG, Fröhling S. Biology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours. Semin Cancer Biol. 2022 Sep;84:228-241. doi: 10.1016/j.semcancer.2022.05.011. Epub 2022 May 25. Review. PubMed PMID: 35643220.

4. Heilig CE, Laßmann A, Mughal SS, Mock A, Pirmann S, Teleanu V, Renner M, Andresen C, Köhler BC, Aybey B, Bauer S, Siveke JT, Hamacher R, Folprecht G, Richter S, Schröck E, Brandts CH, Ahrens M, Hohenberger P, Egerer G, Kindler T, Boerries M, Illert AL, von Bubnoff N, Apostolidis L, Jost PJ, Westphalen CB, Weichert W, Keilholz U, Klauschen F, Beck K, Winter U, Richter D, Möhrmann L, Bitzer M, Schulze-Osthoff K, Brors B, Mechtersheimer G, Kreutzfeldt S, Heining C, Lipka DB, Stenzinger A, Schlenk RF, Horak P, Glimm H, Hübschmann D, Fröhling S. Gene expression-based prediction of pazopanib efficacy in sarcoma. Eur J Cancer. 2022 Jun 25;172:107-118. doi: 10.1016/j.ejca.2022.05.025. [Epub ahead of print] PubMed PMID: 35763870.

5. Frank L, Rademacher A, Mücke N, Tirier SM, Koeleman E, Knotz C, Schumacher S, Stainczyk SA, Westermann F, Fröhling S, Chudasama P, Rippe K. ALT-FISH quantifies alternative lengthening of telomeres activity by imaging of single-stranded repeats. Nucleic Acids Res. 2022 Jun 24;50(11):e61. doi: 10.1093/nar/gkac113. PubMed PMID: 35188570.

6. Rempel E, Kluck K, Beck S, Ourailidis I, Kazdal D, Neumann O, Volckmar AL, Kirchner M, Goldschmid H, Pfarr N, Weichert W, Hübschmann D, Fröhling S, Sutter C, Schaaf CP, Schirmacher P, Endris V, Stenzinger A, Budczies J. Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD). NPJ Precis Oncol. 2022 Jun 9;6(1):36. doi: 10.1038/s41698-022-00276-6. PubMed PMID: 35681079.

7. Reissig TM, Uhrig S, Jost PJ, Luchini C, Vicentini C, Liffers ST, Allgäuer M, Adsay V, Scarpa A, Lawlor RT, Fröhling S, Stenzinger A, Klöppel G, Schildhaus HU, Siveke JT. MCL1 as putative target in pancreatoblastoma. Virchows Arch. 2022 Jun 7;. doi: 10.1007/s00428-022-03349-w. [Epub ahead of print] PubMed PMID: 35668118.

8.   Horak P, Leichsenring J, Goldschmid H, Kreutzfeldt S, Kazdal D, Teleanu V, Endris V, Gieldon L, Allgäuer M, Volckmar AL, Dikow N, Renner M, Kirchner M, Penzel R, Ploeger C, Brandt R, Seker-Cin H, Budczies J, Heilig CE, Neumann O, Schaaf CP, Schirmacher P, Fröhling S, Stenzinger A. Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. Genes Chromosomes Cancer. 2022 Jun;61(6):303-313. doi: 10.1002/gcc.22987. Epub 2021 Aug 9. Review. PubMed PMID: 34331337.

9.  Niger M, Nichetti F, Casadei-Gardini A, Morano F, Pircher C, Tamborini E, Perrone F, Canale M, Lipka DB, Vingiani A, Agnelli L, Dobberkau A, Hüllein J, Korell F, Heilig CE, Pusceddu S, Corti F, Droz M, Ulivi P, Prisciandaro M, Antista M, Bini M, Cattaneo L, Milione M, Glimm H, Köhler BC, Pruneri G, Hübschmann D, Fröhling S, Mazzaferro V, Pietrantonio F, Di Bartolomeo M, de Braud F. MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers. Mol Oncol. 2022 May 27;. doi: 10.1002/1878-0261.13256. [Epub ahead of print] PubMed PMID: 35621918.

10. van der Graaf WTA, Tesselaar MET, McVeigh TP, Oyen WJG, Fröhling S. Biology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours. Semin Cancer Biol. 2022 May 25;. doi: 10.1016/j.semcancer.2022.05.011. [Epub ahead of print] Review. PubMed PMID: 35643220.

11. Wästerlid T, Cavelier L, Haferlach C, Konopleva M, Fröhling S, Östling P, Bullinger L, Fioretos T, Smedby KE. Application of precision medicine in clinical routine in haematology-Challenges and opportunities. J Intern Med. 2022 May 22;. doi: 10.1111/joim.13508. [Epub ahead of print] Review. PubMed PMID: 35599019.

12. Rosenquist R, Fröhling S, Stamatopoulos K. Precision medicine in cancer: A paradigm shift. Semin Cancer Biol. 2022 May 18;. doi: 10.1016/j.semcancer.2022.05.008. [Epub ahead of print] PubMed PMID: 35597437.

13. Schedel A, Friedrich UA, Morcos MNF, Wagener R, Mehtonen J, Watrin T, Saitta C, Brozou T, Michler P, Walter C, Försti A, Baksi A, Menzel M, Horak P, Paramasivam N, Fazio G, Autry RJ, Fröhling S, Suttorp M, Gertzen C, Gohlke H, Bhatia S, Wadt K, Schmiegelow K, Dugas M, Richter D, Glimm H, Heinäniemi M, Jessberger R, Cazzaniga G, Borkhardt A, Hauer J, Auer F. Recurrent Germline Variant in RAD21 Predisposes Children to Lymphoblastic Leukemia or Lymphoma. Int J Mol Sci. 2022 May 5;23(9). doi: 10.3390/ijms23095174. PubMed PMID: 35563565; PubMed Central PMCID: PMC9106003.

14. Hauser K, Kurz A, Haggenmüller S, Maron RC, von Kalle C, Utikal JS, Meier F, Hobelsberger S, Gellrich FF, Sergon M, Hauschild A, French LE, Heinzerling L, Schlager JG, Ghoreschi K, Schlaak M, Hilke FJ, Poch G, Kutzner H, Berking C, Heppt MV, Erdmann M, Haferkamp S, Schadendorf D, Sondermann W, Goebeler M, Schilling B, Kather JN, Fröhling S, Lipka DB, Hekler A, Krieghoff-Henning E, Brinker TJ. Explainable artificial intelligence in skin cancer recognition: A systematic review. Eur J Cancer. 2022 May;167:54-69. doi: 10.1016/j.ejca.2022.02.025. Epub 2022 Apr 5. Review. PubMed PMID: 35390650.

15. Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, Razzak A, Braña I, De Petris L, Yachnin J, Baird RD, Loriot Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, Vernieri C, Masucci M, Villalobos X, Chavarria E, Balmaña J, Apolone G, Caldas C, Bergh J, Ernberg I, Fröhling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtiö J. Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer. 2022 May;3(5):649. doi: 10.1038/s43018-022-00378-x. PubMed PMID: 35449310.

16. Ball M, Christopoulos P, Kirchner M, Allgäuer M, Brandt R, Winter H, Heußel CP, Herth F, Fröhling S, Savai R, Kriegsmann M, Schirmacher P, Peters S, Thomas M, Stenzinger A, Kazdal D. Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report. Cold Spring Harb Mol Case Stud. 2022 Apr;8(3). doi: 10.1101/mcs.a006156. Print 2022 Apr. PubMed PMID: 35058282; PubMed Central PMCID: PMC9059782.

17. Nitsch L, Jensen P, Yoon H, Koeppel J, Burman SSR, Fischer ES, Scholl C, Fröhling S, Słabicki M. BTB_BCL6 dimers as building blocks for reversible drug-induced protein oligomerization. Cell Rep Methods. 2022 Apr 25;2(4):100193. doi: 10.1016/j.crmeth.2022.100193. eCollection 2022 Apr 25. PubMed PMID: 35497498; PubMed Central PMCID: PMC9046236.

18. Berthold R, Isfort I, Erkut C, Heinst L, Grünewald I, Wardelmann E, Kindler T, Åman P, Grünewald TGP, Cidre-Aranaz F, Trautmann M, Fröhling S, Scholl C, Hartmann W. Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma. Oncogenesis. 2022 Apr 22;11(1):20. doi: 10.1038/s41389-022-00394-7. PubMed PMID: 35459264; PubMed Central PMCID: PMC9033823.

19. Simon M, Mughal SS, Horak P, Uhrig S, Buchloh J, Aybey B, Stenzinger A, Glimm H, Fröhling S, Brors B, Imbusch CD. Correction to: Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations. J Transl Med. 2022 Apr 2;20(1):152. doi: 10.1186/s12967-022-03316-8. PubMed PMID: 35366909; PubMed Central PMCID: PMC8977019.

20. Wessels F, Kuntz S, Krieghoff-Henning E, Schmitt M, Braun V, Worst TS, Neuberger M, Steeg M, Gaiser T, Fröhling S, Michel MS, Nuhn P, Brinker TJ. Artificial intelligence to predict oncological outcome directly from hematoxylin & eosin-stained slides in urology: a systematic review. Minerva Urol Nephrol. 2022 Mar 11;. doi: 10.23736/S2724-6051.22.04758-9. [Epub ahead of print] PubMed PMID: 35274903.

21. Maurus K, Kosnopfel C, Kneitz H, Appenzeller S, Schrama D, Glutsch V, Roth S, Gerhard-Hartmann E, Rosenfeldt M, Möhrmann L, Fröhlich M, Hübschmann D, Stenzinger A, Glimm H, Fröhling S, Goebeler M, Rosenwald A, Kutzner H, Schilling B. Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen-activated protein kinase pathway. Br J Dermatol. 2022 Mar;186(3):553-563. doi: 10.1111/bjd.20869. Epub 2021 Dec 21. PubMed PMID: 34726260.

22. Brinker TJ, Schmitt M, Krieghoff-Henning EI, Barnhill R, Beltraminelli H, Braun SA, Carr R, Fernandez-Figueras MT, Ferrara G, Fraitag S, Gianotti R, Llamas-Velasco M, Müller CSL, Perasole A, Requena L, Sangueza OP, Santonja C, Starz H, Vale E, Weyers W, Hekler A, Kather JN, Fröhling S, Krahl D, Holland-Letz T, Utikal JS, Saggini A, Kutzner H. Diagnostic performance of artificial intelligence for histologic melanoma recognition compared to 18 international expert pathologists. J Am Acad Dermatol. 2022 Mar;86(3):640-642. doi: 10.1016/j.jaad.2021.02.009. Epub 2021 Feb 11. PubMed PMID: 33581189.

23. Tamborero D, Dienstmann R, Rachid MH, Boekel J, Lopez-Fernandez A, Jonsson M, Razzak A, Braña I, De Petris L, Yachnin J, Baird RD, Loriot Y, Massard C, Martin-Romano P, Opdam F, Schlenk RF, Vernieri C, Masucci M, Villalobos X, Chavarria E, Balmaña J, Apolone G, Caldas C, Bergh J, Ernberg I, Fröhling S, Garralda E, Karlsson C, Tabernero J, Voest E, Rodon J, Lehtiö J. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nat Cancer. 2022 Feb;3(2):251-261. doi: 10.1038/s43018-022-00332-x. Epub 2022 Feb 24. PubMed PMID: 35221333; PubMed Central PMCID: PMC8882467.

24. Frank L, Rademacher A, Mücke N, Tirier SM, Koeleman E, Knotz C, Schumacher S, Stainczyk SA, Westermann F, Fröhling S, Chudasama P, Rippe K. ALT-FISH quantifies alternative lengthening of telomeres activity by imaging of single-stranded repeats. Nucleic Acids Res. 2022 Feb 21;. doi: 10.1093/nar/gkac113. [Epub ahead of print] PubMed PMID: 35188570.

25. Benedikt Westphalen C, Bokemeyer C, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke JT, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, Loges S. Corrigendum to "Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'" [European Journal of Cancer 135 (2020) 1-7]. Eur J Cancer. 2022 Feb;162:245-246. doi: 10.1016/j.ejca.2021.11.014. Epub 2021 Dec 22. PubMed PMID: 34953660.

26. Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgäuer M, Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Goldmann T, Fröhling S, Wermke M, Waller CF, Tufman A, Reck M, Peters S, Schirmacher P, Thomas M, Christopoulos P, Stenzinger A. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer Immunol Immunother. 2022 Feb;71(2):251-265. doi: 10.1007/s00262-021-02981-w. Epub 2021 Jun 14. PubMed PMID: 34125345; PubMed Central PMCID: PMC8783861.

27. Schneider L, Laiouar-Pedari S, Kuntz S, Krieghoff-Henning E, Hekler A, Kather JN, Gaiser T, Fröhling S, Brinker TJ. Integration of deep learning-based image analysis and genomic data in cancer pathology: A systematic review. Eur J Cancer. 2022 Jan;160:80-91. doi: 10.1016/j.ejca.2021.10.007. Epub 2021 Nov 19. PubMed PMID: 34810047.

1. Heilig CE, Horak P, Kreutzfeldt S, Teleanu V, Mock A, Renner M, Bhatti IA, Hutter B, Hüllein J, Fröhlich M, Uhrig S, Süße H, Heiligenthal L, Ochsenreither S, Illert AL, Vogel A, Desuki A, Heinemann V, Heidegger S, Bitzer M, Scheytt M, Brors B, Hübschmann D, Baretton G, Stenzinger A, Steindorf K, Benner A, Jäger D, Heining C, Glimm H, Fröhling S, Schlenk RF. Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial. ESMO Open. 2021 Dec;6(6):100310. doi: 10.1016/j.esmoop.2021.100310. Epub 2021 Nov 20. PubMed PMID: 34808524; PubMed Central PMCID: PMC8609144.

2. Horak P, Uhrig S, Witzel M, Gil-Farina I, Hutter B, Rath T, Gieldon L, Balasubramanian GP, Pastor X, Heilig CE, Richter D, Schröck E, Ball CR, Brors B, Braun CJ, Albert MH, Scholl C, von Kalle C, Schmidt M, Fröhling S, Klein C, Glimm H. Publisher Correction: Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia. Leukemia. 2021 Dec;35(12):3633. doi: 10.1038/s41375-021-01364-5. PubMed PMID: 34785797; PubMed Central PMCID: PMC8632670.

3. Koelsche C, Benhamida JK, Kommoss FKF, Stichel D, Jones DTW, Pfister SM, Heilig CE, Fröhling S, Stenzinger A, Buslei R, Mentzel T, Baumhoer D, Ladanyi M, Antonescu CR, Flucke U, Gorp JV, Bode-Lesniewska B, Deimling AV, Mechtersheimer G. Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature. Mod Pathol. 2021 Dec;34(12):2122-2129. doi: 10.1038/s41379-021-00874-y. Epub 2021 Jul 26. PubMed PMID: 34312479; PubMed Central PMCID: PMC8592836.

4. Westphal D, Garzarolli M, Sergon M, Horak P, Hutter B, Becker JC, Wiegel M, Maczey E, Blum S, Grosche-Schlee S, Rütten A, Ugurel S, Stenzinger A, Glimm H, Aust D, Baretton G, Beissert S, Fröhling S, Redler S, Surowy H, Meier F. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma. Br J Dermatol. 2021 Dec;185(6):1186-1199. doi: 10.1111/bjd.20604. Epub 2021 Aug 18. PubMed PMID: 34185311.

5. Fröhling S. Interdisciplinary team science to understand and intercept rare cancers. Mol Cell Oncol. 2021;8(6):1997331. doi: 10.1080/23723556.2021.1997331. eCollection 2021. PubMed PMID: 35419478; PubMed Central PMCID: PMC8997247.

6. Borchert F, Mock A, Tomczak A, Hügel J, Alkarkoukly S, Knurr A, Volckmar AL, Stenzinger A, Schirmacher P, Debus J, Jäger D, Longerich T, Fröhling S, Eils R, Bougatf N, Sax U, Schapranow MP. Knowledge bases and software support for variant interpretation in precision oncology. Brief Bioinform. 2021 Nov 5;22(6). doi: 10.1093/bib/bbab246. PubMed PMID: 34125166; PubMed Central PMCID: PMC8575010.

7. Borchert F, Mock A, Tomczak A, Hügel J, Alkarkoukly S, Knurr A, Volckmar AL, Stenzinger A, Schirmacher P, Debus J, Jäger D, Longerich T, Fröhling S, Eils R, Bougatf N, Sax U, Schapranow MP. Knowledge bases and software support for variant interpretation in precision oncology. Brief Bioinform. 2021 Nov 5;22(6). doi: 10.1093/bib/bbab134. PubMed PMID: 33971666; PubMed Central PMCID: PMC8574624.

8. Kiehl L, Kuntz S, Höhn J, Jutzi T, Krieghoff-Henning E, Kather JN, Holland-Letz T, Kopp-Schneider A, Chang-Claude J, Brobeil A, von Kalle C, Fröhling S, Alwers E, Brenner H, Hoffmeister M, Brinker TJ. Deep learning can predict lymph node status directly from histology in colorectal cancer. Eur J Cancer. 2021 Nov;157:464-473. doi: 10.1016/j.ejca.2021.08.039. Epub 2021 Oct 11. PubMed PMID: 34649117.

9. Horak P, Leichsenring J, Kreutzfeldt S, Kazdal D, Teleanu V, Endris V, Volckmar AL, Renner M, Kirchner M, Heilig CE, Neumann O, Schirmacher P, Fröhling S, Stenzinger A. Erratum zu: Varianteninterpretation in dermolekularen Pathologie und Onkologie. Pathologe. 2021 Nov;42(6):602. doi: 10.1007/s00292-021-01002-y. PubMed PMID: 34605937.

10. Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hüllein J, Fröhlich M, Uhrig S, Jahn A, Rump A, Gieldon L, Möhrmann L, Hanf D, Teleanu V, Heilig CE, Lipka DB, Allgäuer M, Ruhnke L, Laßmann A, Endris V, Neumann O, Penzel R, Beck K, Richter D, Winter U, Wolf S, Pfütze K, Geörg C, Meißburger B, Buchhalter I, Augustin M, Aulitzky WE, Hohenberger P, Kroiss M, Schirmacher P, Schlenk RF, Keilholz U, Klauschen F, Folprecht G, Bauer S, Siveke JT, Brandts CH, Kindler T, Boerries M, Illert AL, von Bubnoff N, Jost PJ, Spiekermann K, Bitzer M, Schulze-Osthoff K, von Kalle C, Klink B, Brors B, Stenzinger A, Schröck E, Hübschmann D, Weichert W, Glimm H, Fröhling S. Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discov. 2021 Nov;11(11):2780-2795. doi: 10.1158/2159-8290.CD-21-0126. Epub 2021 Jun 10. PubMed PMID: 34112699.

11. Homan CC, King-Smith SL, Lawrence DM, Arts P, Feng J, Andrews J, Armstrong M, Ha T, Dobbins J, Drazer MW, Yu K, Bödör C, Cantor A, Cazzola M, Degelman E, DiNardo CD, Duployez N, Favier R, Fröhling S, Fitzgibbon J, Klco JM, Krämer A, Kurokawa M, Lee J, Malcovati L, Morgan NV, Natsoulis G, Owen C, Patel KP, Preudhomme C, Raslova H, Rienhoff H, Ripperger T, Schulte R, Tawana K, Velloso E, Yan B, Liu P, Godley LA, Schreiber AW, Hahn CN, Scott HS, Brown AL. The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica. 2021 Nov 1;106(11):3004-3007. doi: 10.3324/haematol.2021.278762. PubMed PMID: 34233450; PubMed Central PMCID: PMC8561292.

12. Ringborg U, Berns A, Celis JE, Heitor M, Tabernero J, Schüz J, Baumann M, Henrique R, Aapro M, Basu P, Beets-Tan R, Besse B, Cardoso F, Carneiro F, van den Eede G, Eggermont A, Fröhling S, Galbraith S, Garralda E, Hanahan D, Hofmarcher T, Jönsson B, Kallioniemi O, Kásler M, Kondorosi E, Korbel J, Lacombe D, Carlos Machado J, Martin-Moreno JM, Meunier F, Nagy P, Nuciforo P, Oberst S, Oliveiera J, Papatriantafyllou M, Ricciardi W, Roediger A, Ryll B, Schilsky R, Scocca G, Seruca R, Soares M, Steindorf K, Valentini V, Voest E, Weiderpass E, Wilking N, Wren A, Zitvogel L. The Porto European Cancer Research Summit 2021. Mol Oncol. 2021 Oct;15(10):2507-2543. doi: 10.1002/1878-0261.13078. Epub 2021 Sep 13. PubMed PMID: 34515408; PubMed Central PMCID: PMC8486569.

13. Haggenmüller S, Maron RC, Hekler A, Utikal JS, Barata C, Barnhill RL, Beltraminelli H, Berking C, Betz-Stablein B, Blum A, Braun SA, Carr R, Combalia M, Fernandez-Figueras MT, Ferrara G, Fraitag S, French LE, Gellrich FF, Ghoreschi K, Goebeler M, Guitera P, Haenssle HA, Haferkamp S, Heinzerling L, Heppt MV, Hilke FJ, Hobelsberger S, Krahl D, Kutzner H, Lallas A, Liopyris K, Llamas-Velasco M, Malvehy J, Meier F, Müller CSL, Navarini AA, Navarrete-Dechent C, Perasole A, Poch G, Podlipnik S, Requena L, Rotemberg VM, Saggini A, Sangueza OP, Santonja C, Schadendorf D, Schilling B, Schlaak M, Schlager JG, Sergon M, Sondermann W, Soyer HP, Starz H, Stolz W, Vale E, Weyers W, Zink A, Krieghoff-Henning E, Kather JN, von Kalle C, Lipka DB, Fröhling S, Hauschild A, Kittler H, Brinker TJ. Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. Eur J Cancer. 2021 Oct;156:202-216. doi: 10.1016/j.ejca.2021.06.049. Epub 2021 Sep 8. PubMed PMID: 34509059.

14. Kirchner M, Kluck K, Brandt R, Volckmar AL, Penzel R, Kazdal D, Endris V, Neumann O, Seker-Cin H, Goldschmid H, Glade J, Allgäuer M, Kriegsmann M, Winter H, Muley T, Perner S, Frost N, Reck M, Fröhling S, Schirmacher P, Thomas M, Budczies J, Christopoulos P, Stenzinger A. The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma. ESMO Open. 2021 Oct;6(5):100253. doi: 10.1016/j.esmoop.2021.100253. Epub 2021 Sep 3. PubMed PMID: 34487971; PubMed Central PMCID: PMC8426209.

15. Brinker TJ, Kiehl L, Schmitt M, Jutzi TB, Krieghoff-Henning EI, Krahl D, Kutzner H, Gholam P, Haferkamp S, Klode J, Schadendorf D, Hekler A, Fröhling S, Kather JN, Haggenmüller S, von Kalle C, Heppt M, Hilke F, Ghoreschi K, Tiemann M, Wehkamp U, Hauschild A, Weichenthal M, Utikal JS. Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours. Eur J Cancer. 2021 Sep;154:227-234. doi: 10.1016/j.ejca.2021.05.026. Epub 2021 Jul 20. PubMed PMID: 34298373.

16. Kuntz S, Krieghoff-Henning E, Kather JN, Jutzi T, Höhn J, Kiehl L, Hekler A, Alwers E, von Kalle C, Fröhling S, Utikal JS, Brenner H, Hoffmeister M, Brinker TJ. Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review. Eur J Cancer. 2021 Sep;155:200-215. doi: 10.1016/j.ejca.2021.07.012. Epub 2021 Aug 11. PubMed PMID: 34391053.

17. Maron RC, Schlager JG, Haggenmüller S, von Kalle C, Utikal JS, Meier F, Gellrich FF, Hobelsberger S, Hauschild A, French L, Heinzerling L, Schlaak M, Ghoreschi K, Hilke FJ, Poch G, Heppt MV, Berking C, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Goebeler M, Krieghoff-Henning E, Hekler A, Fröhling S, Lipka DB, Kather JN, Brinker TJ. A benchmark for neural network robustness in skin cancer classification. Eur J Cancer. 2021 Sep;155:191-199. doi: 10.1016/j.ejca.2021.06.047. Epub 2021 Aug 11. PubMed PMID: 34388516.

18. Wessels F, Schmitt M, Krieghoff-Henning E, Jutzi T, Worst TS, Waldbillig F, Neuberger M, Maron RC, Steeg M, Gaiser T, Hekler A, Utikal JS, von Kalle C, Fröhling S, Michel MS, Nuhn P, Brinker TJ. Deep learning approach to predict lymph node metastasis directly from primary tumour histology in prostate cancer. BJU Int. 2021 Sep;128(3):352-360. doi: 10.1111/bju.15386. Epub 2021 May 5. PubMed PMID: 33706408.

19. Willis F, Musa J, Schimmack S, Hinz U, Mechtersheimer G, Uhl M, Schmidt T, Fröhling S, Büchler MW, Schneider M. Outcome after surgical resection of multiple recurrent retroperitoneal soft tissue sarcoma. Eur J Surg Oncol. 2021 Aug;47(8):2189-2200. doi: 10.1016/j.ejso.2021.04.040. Epub 2021 May 4. PubMed PMID: 33980415.

20. Moratin J, Mock A, Obradovic S, Metzger K, Flechtenmacher C, Zaoui K, Fröhling S, Jäger D, Krauss J, Hoffmann J, Freier K, Horn D, Hess J, Freudlsperger C. Digital Pathology Scoring of Immunohistochemical Staining Reliably Identifies Prognostic Markers and Anatomical Associations in a Large Cohort of Oral Cancers. Front Oncol. 2021;11:712944. doi: 10.3389/fonc.2021.712944. eCollection 2021. PubMed PMID: 34395287; PubMed Central PMCID: PMC8359738.

21. Vangala D, Ladigan S, Liffers ST, Noseir S, Maghnouj A, Götze TM, Verdoodt B, Klein-Scory S, Godfrey L, Zowada MK, Huerta M, Edelstein DL, de Villarreal JM, Marqués M, Kumbrink J, Jung A, Schiergens T, Werner J, Heinemann V, Stintzing S, Lindoerfer D, Mansmann U, Pohl M, Teschendorf C, Bernhardt C, Wolters H, Stern J, Usta S, Viebahn R, Admard J, Casadei N, Fröhling S, Ball CR, Siveke JT, Glimm H, Tannapfel A, Schmiegel W, Hahn SA. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models. Genome Med. 2021 Jul 16;13(1):116. doi: 10.1186/s13073-021-00926-7. PubMed PMID: 34271981; PubMed Central PMCID: PMC8283888.

22. Höhn J, Hekler A, Krieghoff-Henning E, Kather JN, Utikal JS, Meier F, Gellrich FF, Hauschild A, French L, Schlager JG, Ghoreschi K, Wilhelm T, Kutzner H, Heppt M, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Maron RC, Schmitt M, Jutzi T, Fröhling S, Lipka DB, Brinker TJ. Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review. J Med Internet Res. 2021 Jul 2;23(7):e20708. doi: 10.2196/20708. Review. PubMed PMID: 34255646; PubMed Central PMCID: PMC8285747.

23. Horak P, Leichsenring J, Kreutzfeldt S, Kazdal D, Teleanu V, Endris V, Volckmar AL, Renner M, Kirchner M, Heilig CE, Neumann O, Schirmacher P, Fröhling S, Stenzinger A. [Variant interpretation in molecular pathology and oncology : An introduction]. Pathologe. 2021 Jul;42(4):369-379. doi: 10.1007/s00292-021-00938-5. Epub 2021 May 3. Review. PubMed PMID: 33938987.

24. Bertero L, Righi L, Collemi G, Koelsche C, Hou Y, Stichel D, Schrimpf D, Flucke U, Petersen I, Vokuhl C, Fröhling S, Bironzo P, Scagliotti GV, Cassoni P, Papotti M, von Deimling A. DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics. J Mol Diagn. 2021 Jul;23(7):834-846. doi: 10.1016/j.jmoldx.2021.04.002. Epub 2021 Apr 20. PubMed PMID: 33887463.

25. Mock A, Plath M, Moratin J, Tapken MJ, Jäger D, Krauss J, Fröhling S, Hess J, Zaoui K. EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck Cancers. Front Oncol. 2021;11:678966. doi: 10.3389/fonc.2021.678966. eCollection 2021. PubMed PMID: 34178665; PubMed Central PMCID: PMC8226088.

26. Stenzinger A, Edsjö A, Ploeger C, Friedman M, Fröhling S, Wirta V, Seufferlein T, Botling J, Duyster J, Akhras M, Thimme R, Fioretos T, Bitzer M, Cavelier L, Schirmacher P, Malek N, Rosenquist R. Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Semin Cancer Biol. 2021 May 24;. doi: 10.1016/j.semcancer.2021.05.026. [Epub ahead of print] PubMed PMID: 34033893.

27. Simon M, Mughal SS, Horak P, Uhrig S, Buchloh J, Aybey B, Stenzinger A, Glimm H, Fröhling S, Brors B, Imbusch CD. Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations. J Transl Med. 2021 May 12;19(1):204. doi: 10.1186/s12967-021-02858-7. PubMed PMID: 33980253; PubMed Central PMCID: PMC8117561.

28. Mock-Ohnesorge J, Mock A, Hackert T, Fröhling S, Schenz J, Poschet G, Jäger D, Büchler MW, Uhle F, Weigand MA. Perioperative changes in the plasma metabolome of patients receiving general anesthesia for pancreatic cancer surgery. Oncotarget. 2021 May 11;12(10):996-1010. doi: 10.18632/oncotarget.27956. eCollection 2021 May 11. PubMed PMID: 34012512; PubMed Central PMCID: PMC8121611.

29. Höhn J, Krieghoff-Henning E, Jutzi TB, von Kalle C, Utikal JS, Meier F, Gellrich FF, Hobelsberger S, Hauschild A, Schlager JG, French L, Heinzerling L, Schlaak M, Ghoreschi K, Hilke FJ, Poch G, Kutzner H, Heppt MV, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Goebeler M, Hekler A, Fröhling S, Lipka DB, Kather JN, Krahl D, Ferrara G, Haggenmüller S, Brinker TJ. Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification. Eur J Cancer. 2021 May;149:94-101. doi: 10.1016/j.ejca.2021.02.032. Epub 2021 Apr 7. PubMed PMID: 33838393.

30. Hübschmann D, Jopp-Saile L, Andresen C, Krämer S, Gu Z, Heilig CE, Kreutzfeldt S, Teleanu V, Fröhling S, Eils R, Schlesner M. Analysis of mutational signatures with yet another package for signature analysis. Genes Chromosomes Cancer. 2021 May;60(5):314-331. doi: 10.1002/gcc.22918. Epub 2020 Dec 31. PubMed PMID: 33222322.

31. Hanf D, Heining C, Laaber K, Nebelung H, Uhrig S, Hutter B, Jahn A, Richter D, Aust D, Herbst F, Fröhling S, Glimm H, Folprecht G. Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3^G623R Solvent-Front Mutation. JCO Precis Oncol. 2021;5. doi: 10.1200/PO.20.00278. eCollection 2021. PubMed PMID: 34250401; PubMed Central PMCID: PMC8232550.

32. Hlevnjak M, Schulze M, Elgaafary S, Fremd C, Michel L, Beck K, Pfütze K, Richter D, Wolf S, Horak P, Kreutzfeldt S, Pixberg C, Hutter B, Ishaque N, Hirsch S, Gieldon L, Stenzinger A, Springfeld C, Smetanay K, Seitz J, Mavratzas A, Brors B, Kirsten R, Schuetz F, Fröhling S, Sinn HP, Jäger D, Thewes V, Zapatka M, Lichter P, Schneeweiss A. CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. JCO Precis Oncol. 2021;5. doi: 10.1200/PO.20.00248. eCollection 2021. PubMed PMID: 34036222; PubMed Central PMCID: PMC8140780.

33. Volckmar AL, Christopoulos P, Kirchner M, Allgäuer M, Neumann O, Budczies J, Rempel E, Horak P, Glade J, Goldschmid H, Seker-Cin H, Brandt R, Kriegsmann M, Leichsenring J, Winter H, Faehling M, Fischer JR, Heußel CP, Herth F, Brummer T, Fröhling S, Schirmacher P, Thomas M, Endris V, Penzel R, Kazdal D, Bochtler T, Stenzinger A. Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field. Lung Cancer. 2021 Apr;154:131-141. doi: 10.1016/j.lungcan.2021.02.022. Epub 2021 Feb 19. PubMed PMID: 33667718.

34. Lenschow C, Fuss CT, Kircher S, Buck A, Kickuth R, Reibetanz J, Wiegering A, Stenzinger A, Hübschmann D, Germer CT, Fassnacht M, Fröhling S, Schlegel N, Kroiss M. Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. Front Endocrinol (Lausanne). 2021;12:643328. doi: 10.3389/fendo.2021.643328. eCollection 2021. PubMed PMID: 33833736; PubMed Central PMCID: PMC8021949.

35. Wahjudi LW, Bernhardt S, Abnaof K, Horak P, Kreutzfeldt S, Heining C, Borgoni S, Becki C, Berg D, Richter D, Hutter B, Uhrig S, Pfütze K, Leichsenring J, Glimm H, Brors B, von Kalle C, Stenzinger A, Korf U, Fröhling S, Wiemann S. Integrating proteomics into precision oncology. Int J Cancer. 2021 Mar 15;148(6):1438-1451. doi: 10.1002/ijc.33301. Epub 2020 Sep 25. PubMed PMID: 32949162.

36. Uhrig S, Ellermann J, Walther T, Burkhardt P, Fröhlich M, Hutter B, Toprak UH, Neumann O, Stenzinger A, Scholl C, Fröhling S, Brors B. Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Res. 2021 Mar;31(3):448-460. doi: 10.1101/gr.257246.119. Epub 2021 Jan 13. PubMed PMID: 33441414; PubMed Central PMCID: PMC7919457.

37. Maron RC, Haggenmüller S, von Kalle C, Utikal JS, Meier F, Gellrich FF, Hauschild A, French LE, Schlaak M, Ghoreschi K, Kutzner H, Heppt MV, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Hekler A, Krieghoff-Henning E, Kather JN, Fröhling S, Lipka DB, Brinker TJ. Robustness of convolutional neural networks in recognition of pigmented skin lesions. Eur J Cancer. 2021 Mar;145:81-91. doi: 10.1016/j.ejca.2020.11.020. Epub 2021 Jan 7. PubMed PMID: 33423009.

38. Seidensaal K, Kieser M, Hommertgen A, Jaekel C, Harrabi SB, Herfarth K, Mechtesheimer G, Lehner B, Schneider M, Nienhueser H, Fröhling S, Egerer G, Debus J, Uhl M. Neoadjuvant irradiation of retroperitoneal soft tissue sarcoma with ions (Retro-Ion): study protocol for a randomized phase II pilot trial. Trials. 2021 Feb 12;22(1):134. doi: 10.1186/s13063-021-05069-z. PubMed PMID: 33579340; PubMed Central PMCID: PMC7881463.

39. Schmitt M, Maron RC, Hekler A, Stenzinger A, Hauschild A, Weichenthal M, Tiemann M, Krahl D, Kutzner H, Utikal JS, Haferkamp S, Kather JN, Klauschen F, Krieghoff-Henning E, Fröhling S, von Kalle C, Brinker TJ. Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study. J Med Internet Res. 2021 Feb 2;23(2):e23436. doi: 10.2196/23436. PubMed PMID: 33528370; PubMed Central PMCID: PMC7886613.

40. Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss DE, Blattner M, Worst B, Heilig CE, Beck K, Horak P, Kreutzfeldt S, Paff E, Stark S, Johann P, Selt F, Ecker J, Sturm D, Pajtler KW, Reinhardt A, Wefers AK, Sievers P, Ebrahimi A, Suwala A, Fernández-Klett F, Casalini B, Korshunov A, Hovestadt V, Kommoss FKF, Kriegsmann M, Schick M, Bewerunge-Hudler M, Milde T, Witt O, Kulozik AE, Kool M, Romero-Pérez L, Grünewald TGP, Kirchner T, Wick W, Platten M, Unterberg A, Uhl M, Abdollahi A, Debus J, Lehner B, Thomas C, Hasselblatt M, Paulus W, Hartmann C, Staszewski O, Prinz M, Hench J, Frank S, Versleijen-Jonkers YMH, Weidema ME, Mentzel T, Griewank K, de Álava E, Martín JD, Gastearena MAI, Chang KT, Low SYY, Cuevas-Bourdier A, Mittelbronn M, Mynarek M, Rutkowski S, Schüller U, Mautner VF, Schittenhelm J, Serrano J, Snuderl M, Büttner R, Klingebiel T, Buslei R, Gessler M, Wesseling P, Dinjens WNM, Brandner S, Jaunmuktane Z, Lyskjær I, Schirmacher P, Stenzinger A, Brors B, Glimm H, Heining C, Tirado OM, Sáinz-Jaspeado M, Mora J, Alonso J, Del Muro XG, Moran S, Esteller M, Benhamida JK, Ladanyi M, Wardelmann E, Antonescu C, Flanagan A, Dirksen U, Hohenberger P, Baumhoer D, Hartmann W, Vokuhl C, Flucke U, Petersen I, Mechtersheimer G, Capper D, Jones DTW, Fröhling S, Pfister SM, von Deimling A. Sarcoma classification by DNA methylation profiling. Nat Commun. 2021 Jan 21;12(1):498. doi: 10.1038/s41467-020-20603-4. PubMed PMID: 33479225; PubMed Central PMCID: PMC7819999.

41. Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgäuer M, Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Fröhling S, Peters S, Seliger B, Schirmacher P, Thomas M, Christopoulos P, Stenzinger A. A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. Oncoimmunology. 2021 Jan 11;10(1):1860586. doi: 10.1080/2162402X.2020.1860586. PubMed PMID: 33520406; PubMed Central PMCID: PMC7808386.

1. Loosen SH, Gaisa NT, Schmeding M, Heining C, Uhrig S, Wirtz TH, Kalverkamp S, Spillner J, Tacke F, Stenzinger A, Glimm H, Fröhling S, Trautwein C, Roderburg C, Longerich T, Neumann UP, Luedde T. Prolonged Survival of a Patient with Advanced-Stage Combined Hepatocellular-Cholangiocarcinoma. Case Rep Gastroenterol. 2020 Sep-Dec;14(3):658-667. doi: 10.1159/000511034. eCollection 2020 Sep-Dec. PubMed PMID: 33442346; PubMed Central PMCID: PMC7772835.

2. Mc Connell L, Gazdova J, Beck K, Srivastava S, Harewood L, Stewart JP, Hübschmann D, Stenzinger A, Glimm H, Heilig CE, Fröhling S, Gonzalez D. Detection of Structural Variants in Circulating Cell-Free DNA from Sarcoma Patients Using Next Generation Sequencing. Cancers (Basel). 2020 Dec 3;12(12). doi: 10.3390/cancers12123627. PubMed PMID: 33287361; PubMed Central PMCID: PMC7761870.

3. Słabicki M, Yoon H, Koeppel J, Nitsch L, Roy Burman SS, Di Genua C, Donovan KA, Sperling AS, Hunkeler M, Tsai JM, Sharma R, Guirguis A, Zou C, Chudasama P, Gasser JA, Miller PG, Scholl C, Fröhling S, Nowak RP, Fischer ES, Ebert BL. Small-molecule-induced polymerization triggers degradation of BCL6. Nature. 2020 Dec;588(7836):164-168. doi: 10.1038/s41586-020-2925-1. Epub 2020 Nov 18. PubMed PMID: 33208943; PubMed Central PMCID: PMC7816212.

4. Jensen P, Carlet M, Schlenk RF, Weber A, Kress J, Brunner I, Słabicki M, Grill G, Weisemann S, Cheng YY, Jeremias I, Scholl C, Fröhling S. Requirement for LIM kinases in acute myeloid leukemia. Leukemia. 2020 Dec;34(12):3173-3185. doi: 10.1038/s41375-020-0943-5. Epub 2020 Jun 26. PubMed PMID: 32591645; PubMed Central PMCID: PMC7612252.

5. Kutzner H, Jutzi TB, Krahl D, Krieghoff-Henning EI, Heppt MV, Hekler A, Schmitt M, Maron RCR, Fröhling S, von Kalle C, Brinker TJ. Überdiagnose von Melanomen - Ursachen, Konsequenzen und Lösungsansätze. J Dtsch Dermatol Ges. 2020 Nov;18(11):1236-1244. doi: 10.1111/ddg.14233_g. Review. PubMed PMID: 33251725.

6. Lehmann LH, Fröhling S. [Mechanisms of cardiotoxicity of oncological therapies]. Internist (Berl). 2020 Nov;61(11):1132-1139. doi: 10.1007/s00108-020-00881-2. Review. PubMed PMID: 33034675.

7. Kutzner H, Jutzi TB, Krahl D, Krieghoff-Henning EI, Heppt MV, Hekler A, Schmitt M, Maron RCR, Fröhling S, von Kalle C, Brinker TJ. Overdiagnosis of melanoma - causes, consequences and solutions. J Dtsch Dermatol Ges. 2020 Nov;18(11):1236-1243. doi: 10.1111/ddg.14233. Epub 2020 Aug 25. Review. PubMed PMID: 32841508.

8. Scherr AL, Mock A, Gdynia G, Schmitt N, Heilig CE, Korell F, Rhadakrishnan P, Hoffmeister P, Metzeler KH, Schulze-Osthoff K, Illert AL, Boerries M, Trojan J, Waidmann O, Falkenhorst J, Siveke J, Jost PJ, Bitzer M, Malek NP, Vecchione L, Jelas I, Brors B, Glimm H, Stenzinger A, Grekova SP, Gehrig T, Schulze-Bergkamen H, Jäger D, Schirmacher P, Heikenwalder M, Goeppert B, Schneider M, Fröhling S, Köhler BC. Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer. Cell Death Dis. 2020 Oct 17;11(10):875. doi: 10.1038/s41419-020-03092-7. PubMed PMID: 33070156; PubMed Central PMCID: PMC7568722.

9. Messerschmidt C, Obermayer B, Klinghammer K, Ochsenreither S, Treue D, Stenzinger A, Glimm H, Fröhling S, Kindler T, Brandts CH, Schulze-Osthoff K, Weichert W, Tinhofer I, Klauschen F, Keilholz U, Beule D, Rieke DT. Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC. Int J Cancer. 2020 Oct 15;147(8):2293-2302. doi: 10.1002/ijc.33123. Epub 2020 Jun 18. PubMed PMID: 32468570.

10. Heilig CE, Badoglio M, Labopin M, Fröhling S, Secondino S, Heinz J, Nicolas-Virelizier E, Blaise D, Korenbaum C, Santoro A, Verbeek M, Krüger W, Siena S, Passweg JR, Di Nicola M, Rifón J, Dreger P, Koehl U, Chabannon C, Pedrazzoli P. Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation. ESMO Open. 2020 Oct;5(5):e000860. doi: 10.1136/esmoopen-2020-000860. PubMed PMID: 33097652; PubMed Central PMCID: PMC7590345.

11. Heilig CE, Horak P, Lipka DB, Mock A, Uhrig S, Kreutzfeldt S, Richter S, Gieldon L, Fröhlich M, Hutter B, Hübschmann D, Teleanu V, Schmier JW, Philipzen J, Beuthien-Baumann B, Schröck E, von Deimling A, Bauer S, Heining C, Mechtersheimer G, Stenzinger A, Brors B, Wardelmann E, Glimm H, Hartmann W, Fröhling S. Germline SDHB-inactivating mutation in gastric spindle cell sarcoma. Genes Chromosomes Cancer. 2020 Oct;59(10):601-608. doi: 10.1002/gcc.22876. Epub 2020 Jun 26. PubMed PMID: 32501622.

12. Horak P, Uhrig S, Witzel M, Gil-Farina I, Hutter B, Rath T, Gieldon L, Balasubramanian GP, Pastor X, Heilig CE, Richter D, Schröck E, Ball CR, Brors B, Braun CJ, Albert MH, Scholl C, von Kalle C, Schmidt M, Fröhling S, Klein C, Glimm H. Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia. Leukemia. 2020 Oct;34(10):2785-2789. doi: 10.1038/s41375-020-0779-z. Epub 2020 Mar 3. PubMed PMID: 32127638; PubMed Central PMCID: PMC8321895.

13. Maron RC, Utikal JS, Hekler A, Hauschild A, Sattler E, Sondermann W, Haferkamp S, Schilling B, Heppt MV, Jansen P, Reinholz M, Franklin C, Schmitt L, Hartmann D, Krieghoff-Henning E, Schmitt M, Weichenthal M, von Kalle C, Fröhling S, Brinker TJ. Artificial Intelligence and Its Effect on Dermatologists' Accuracy in Dermoscopic Melanoma Image Classification: Web-Based Survey Study. J Med Internet Res. 2020 Sep 11;22(9):e18091. doi: 10.2196/18091. PubMed PMID: 32915161; PubMed Central PMCID: PMC7519424.

14. Munkhbaatar E, Dietzen M, Agrawal D, Anton M, Jesinghaus M, Boxberg M, Pfarr N, Bidola P, Uhrig S, Höckendorf U, Meinhardt AL, Wahida A, Heid I, Braren R, Mishra R, Warth A, Muley T, Poh PSP, Wang X, Fröhling S, Steiger K, Slotta-Huspenina J, van Griensven M, Pfeiffer F, Lange S, Rad R, Spella M, Stathopoulos GT, Ruland J, Bassermann F, Weichert W, Strasser A, Branca C, Heikenwalder M, Swanton C, McGranahan N, Jost PJ. MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nat Commun. 2020 Sep 10;11(1):4527. doi: 10.1038/s41467-020-18372-1. PubMed PMID: 32913197; PubMed Central PMCID: PMC7484793.

15. Rippinger N, Fischer C, Haun MW, Rhiem K, Grill S, Kiechle M, Cremer FW, Kast K, Nguyen HP, Ditsch N, Kratz CP, Vogel J, Speiser D, Hettmer S, Glimm H, Fröhling S, Jäger D, Seitz S, Hahne A, Maatouk I, Sutter C, Schmutzler RK, Dikow N, Schott S. Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey. Cancer. 2020 Sep 1;126(17):4032-4041. doi: 10.1002/cncr.33004. Epub 2020 Jun 18. PubMed PMID: 32557628.

16. Słabicki M, Kozicka Z, Petzold G, Li YD, Manojkumar M, Bunker RD, Donovan KA, Sievers QL, Koeppel J, Suchyta D, Sperling AS, Fink EC, Gasser JA, Wang LR, Corsello SM, Sellar RS, Jan M, Gillingham D, Scholl C, Fröhling S, Golub TR, Fischer ES, Thomä NH, Ebert BL. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature. 2020 Sep;585(7824):293-297. doi: 10.1038/s41586-020-2374-x. Epub 2020 Jun 3. PubMed PMID: 32494016; PubMed Central PMCID: PMC7486275.

17. Busch E, Kreutzfeldt S, Agaimy A, Mechtersheimer G, Horak P, Brors B, Hutter B, Fröhlich M, Uhrig S, Mayer P, Schröck E, Stenzinger A, Glimm H, Jäger D, Springfeld C, Fröhling S, Zschäbitz S. Successful BRAF/MEK inhibition in a patient with BRAF^V600E-mutated extrapancreatic acinar cell carcinoma. Cold Spring Harb Mol Case Stud. 2020 Aug;6(4). doi: 10.1101/mcs.a005553. Print 2020 Aug. PubMed PMID: 32843432; PubMed Central PMCID: PMC7476408.

18. de Rojas T, Kasper B, Van der Graaf W, Pfister SM, Bielle F, Ribalta T, Shenjere P, Preusser M, Fröhling S, Golfinopoulos V, Morfouace M, McCabe MG. EORTC SPECTA-AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe. Int J Cancer. 2020 Aug 15;147(4):1180-1184. doi: 10.1002/ijc.32651. Epub 2019 Sep 14. PubMed PMID: 31465545; PubMed Central PMCID: PMC7383917.

19. Westphalen BC, Bokemeyer C, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke JT, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, Loges S. Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'. Eur J Cancer. 2020 Aug;135:1-7. doi: 10.1016/j.ejca.2020.04.019. Epub 2020 Jun 7. Review. PubMed PMID: 32521293.

20. Tamborero D, Dienstmann R, Rachid MH, Boekel J, Baird R, Braña I, De Petris L, Yachnin J, Massard C, Opdam FL, Schlenk R, Vernieri C, Garralda E, Masucci M, Villalobos X, Chavarria E, Calvo F, Fröhling S, Eggermont A, Apolone G, Voest EE, Caldas C, Tabernero J, Ernberg I, Rodon J, Lehtiö J. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Nat Med. 2020 Jul;26(7):992-994. doi: 10.1038/s41591-020-0969-2. PubMed PMID: 32632195.

21. Roider T, Seufert J, Uvarovskii A, Frauhammer F, Bordas M, Abedpour N, Stolarczyk M, Mallm JP, Herbst SA, Bruch PM, Balke-Want H, Hundemer M, Rippe K, Goeppert B, Seiffert M, Brors B, Mechtersheimer G, Zenz T, Peifer M, Chapuy B, Schlesner M, Müller-Tidow C, Fröhling S, Huber W, Anders S, Dietrich S. Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels. Nat Cell Biol. 2020 Jul;22(7):896-906. doi: 10.1038/s41556-020-0532-x. Epub 2020 Jun 15. PubMed PMID: 32541878.

22. van de Haar J, Hoes LR, Coles CE, Seamon K, Fröhling S, Jäger D, Valenza F, de Braud F, De Petris L, Bergh J, Ernberg I, Besse B, Barlesi F, Garralda E, Piris-Giménez A, Baumann M, Apolone G, Soria JC, Tabernero J, Caldas C, Voest EE. Author Correction: Caring for patients with cancer in the COVID-19 era. Nat Med. 2020 Jul;26(7):1146. doi: 10.1038/s41591-020-0948-7. PubMed PMID: 32494062; PubMed Central PMCID: PMC7269160.

23. Kommoss FK, Chang KT, Stichel D, Banito A, Jones DT, Heilig CE, Fröhling S, Sahm F, Stenzinger A, Hartmann W, Mechtersheimer G, Sinn HP, Schmidt D, Kommoss F, von Deimling A, Koelsche C. Endometrial stromal sarcomas with BCOR-rearrangement harbor MDM2 amplifications. J Pathol Clin Res. 2020 Jul;6(3):178-184. doi: 10.1002/cjp2.165. Epub 2020 Apr 30. PubMed PMID: 32352245; PubMed Central PMCID: PMC7339170.

24. Stenzinger A, Endris V, Budczies J, Merkelbach-Bruse S, Kazdal D, Dietmaier W, Pfarr N, Siebolts U, Hummel M, Herold S, Andreas J, Zoche M, Tögel L, Rempel E, Maas J, Merino D, Stewart M, Zaoui K, Schlesner M, Glimm H, Fröhling S, Allen J, Horst D, Baretton G, Wickenhauser C, Tiemann M, Evert M, Moch H, Kirchner T, Büttner R, Schirmacher P, Jung A, Haller F, Weichert W, Dietel M. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study. J Thorac Oncol. 2020 Jul;15(7):1177-1189. doi: 10.1016/j.jtho.2020.01.023. Epub 2020 Feb 29. PubMed PMID: 32119917.

25. Vu T, Straube J, Porter AH, Bywater M, Song A, Ling V, Cooper L, Pali G, Bruedigam C, Jacquelin S, Green J, Magor G, Perkins A, Chalk AM, Walkley CR, Heidel FH, Mukhopadhyay P, Cloonan N, Gröschel S, Mallm JP, Fröhling S, Scholl C, Lane SW. Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia. Nat Commun. 2020 Jun 15;11(1):3021. doi: 10.1038/s41467-020-16840-2. PubMed PMID: 32541670; PubMed Central PMCID: PMC7296000.

26. Seidensaal K, Harrabi SB, Weykamp F, Herfarth K, Welzel T, Mechtersheimer G, Lehner B, Schneider M, Fröhling S, Egerer G, Debus J, Uhl M. Radiotherapy in the treatment of aggressive fibromatosis: experience from a single institution. Radiat Oncol. 2020 Jun 5;15(1):143. doi: 10.1186/s13014-020-01565-9. PubMed PMID: 32503580; PubMed Central PMCID: PMC7275436.

27. Jutzi TB, Krieghoff-Henning EI, Holland-Letz T, Utikal JS, Hauschild A, Schadendorf D, Sondermann W, Fröhling S, Hekler A, Schmitt M, Maron RC, Brinker TJ. Artificial Intelligence in Skin Cancer Diagnostics: The Patients' Perspective. Front Med (Lausanne). 2020;7:233. doi: 10.3389/fmed.2020.00233. eCollection 2020. PubMed PMID: 32671078; PubMed Central PMCID: PMC7326111.

28. Voronina N, Wong JKL, Hübschmann D, Hlevnjak M, Uhrig S, Heilig CE, Horak P, Kreutzfeldt S, Mock A, Stenzinger A, Hutter B, Fröhlich M, Brors B, Jahn A, Klink B, Gieldon L, Sieverling L, Feuerbach L, Chudasama P, Beck K, Kroiss M, Heining C, Möhrmann L, Fischer A, Schröck E, Glimm H, Zapatka M, Lichter P, Fröhling S, Ernst A. The landscape of chromothripsis across adult cancer types. Nat Commun. 2020 May 8;11(1):2320. doi: 10.1038/s41467-020-16134-7. PubMed PMID: 32385320; PubMed Central PMCID: PMC7210959.

29. Hekler A, Kather JN, Krieghoff-Henning E, Utikal JS, Meier F, Gellrich FF, Upmeier Zu Belzen J, French L, Schlager JG, Ghoreschi K, Wilhelm T, Kutzner H, Berking C, Heppt MV, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Izar B, Maron R, Schmitt M, Fröhling S, Lipka DB, Brinker TJ. Effects of Label Noise on Deep Learning-Based Skin Cancer Classification. Front Med (Lausanne). 2020;7:177. doi: 10.3389/fmed.2020.00177. eCollection 2020. PubMed PMID: 32435646; PubMed Central PMCID: PMC7218064.

30. van de Haar J, Hoes LR, Coles CE, Seamon K, Fröhling S, Jäger D, Valenza F, de Braud F, De Petris L, Bergh J, Ernberg I, Besse B, Barlesi F, Garralda E, Piris-Giménez A, Baumann M, Apolone G, Soria JC, Tabernero J, Caldas C, Voest EE. Caring for patients with cancer in the COVID-19 era. Nat Med. 2020 May;26(5):665-671. doi: 10.1038/s41591-020-0874-8. Epub 2020 Apr 16. Review. PubMed PMID: 32405058.

31. Ronellenfitsch MW, Harter PN, Kirchner M, Heining C, Hutter B, Gieldon L, Schittenhelm J, Schuhmann MU, Tatagiba M, Marquardt G, Wagner M, Endris V, Brandts CH, Mautner VF, Schröck E, Weichert W, Brors B, von Deimling A, Mittelbronn M, Steinbach JP, Reuss DE, Glimm H, Stenzinger A, Fröhling S. Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. J Clin Invest. 2020 May 1;130(5):2488-2495. doi: 10.1172/JCI130787. PubMed PMID: 32017710; PubMed Central PMCID: PMC7190903.

32. Hekler A, Utikal JS, Solass W, Schmitt M, Klode J, Schadendorf D, Sondermann W, Franklin C, Bestvater F, Krahl D, von Kalle C, Fröhling S, Brinker TJ. Reply to the letter to the editor: 'Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images'. Eur J Cancer. 2020 May;130:262-264. doi: 10.1016/j.ejca.2019.12.024. Epub 2020 Jan 30. PubMed PMID: 32008919.

33. Willis F, Schimmack S, Uhl M, Haefner MF, Mechtersheimer G, Hinz U, Schmidt T, Debus J, Fröhling S, Schneider M. Significance of intraoperative radiation therapy and high cumulative radiation doses in retroperitoneal soft tissue sarcoma. Eur J Surg Oncol. 2020 May;46(5):905-913. doi: 10.1016/j.ejso.2019.12.014. Epub 2019 Dec 17. PubMed PMID: 31892479.

34. Berger AK, Mughal SS, Allgäuer M, Springfeld C, Hackert T, Weber TF, Naumann P, Hutter B, Horak P, Jahn A, Schröck E, Haag GM, Apostolidis L, Jäger D, Stenzinger A, Fröhling S, Glimm H, Heining C. Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease. Pancreatology. 2020 Apr;20(3):425-432. doi: 10.1016/j.pan.2020.02.017. Epub 2020 Feb 29. PubMed PMID: 32156527.

35. Budczies J, Kazdal D, Allgäuer M, Christopoulos P, Rempel E, Pfarr N, Weichert W, Fröhling S, Thomas M, Peters S, Endris V, Schirmacher P, Stenzinger A. Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. Lung Cancer. 2020 Apr;142:114-119. doi: 10.1016/j.lungcan.2020.01.019. Epub 2020 Feb 1. PubMed PMID: 32143116.

36. Brown AL, Arts P, Carmichael CL, Babic M, Dobbins J, Chong CE, Schreiber AW, Feng J, Phillips K, Wang PPS, Ha T, Homan CC, King-Smith SL, Rawlings L, Vakulin C, Dubowsky A, Burdett J, Moore S, McKavanagh G, Henry D, Wells A, Mercorella B, Nicola M, Suttle J, Wilkins E, Li XC, Michaud J, Brautigan P, Cannon P, Altree M, Jaensch L, Fine M, Butcher C, D'Andrea RJ, Lewis ID, Hiwase DK, Papaemmanuil E, Horwitz MS, Natsoulis G, Rienhoff HY, Patton N, Mapp S, Susman R, Morgan S, Cooney J, Currie M, Popat U, Bochtler T, Izraeli S, Bradstock K, Godley LA, Krämer A, Fröhling S, Wei AH, Forsyth C, Mar Fan H, Poplawski NK, Hahn CN, Scott HS. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Adv. 2020 Mar 24;4(6):1131-1144. doi: 10.1182/bloodadvances.2019000901. PubMed PMID: 32208489; PubMed Central PMCID: PMC7094007.

37.Zielonka M, Debatin D, Rütten A, Fröhling S, Deimling A, Warth A, Toberer F, Enk AH, Hassel JC. Zerebral metastasiertes Dermatofibrosarcoma protuberans. J Dtsch Dermatol Ges. 2020 Feb;18(2):143-146. doi: 10.1111/ddg.13992_g. PubMed PMID: 32026638.

38. Zielonka M, Debatin D, Rütten A, Fröhling S, Deimling A, Warth A, Toberer F, Enk AH, Hassel JC. Cerebral metastases of a dermatofibrosarcoma protuberans. J Dtsch Dermatol Ges. 2020 Feb;18(2):143-145. doi: 10.1111/ddg.13992. Epub 2019 Dec 17. PubMed PMID: 31846212.

39. Mogler C, Koschny R, Heilig CE, Frohling S, Schirmacher P, Weichert W, Pfarr N. Molecular characterization of hepatic epithelioid hemangioendothelioma reveals alterations in various genes involved in DNA repair, epigenetic regulation, signaling pathways, and cell cycle control. Genes Chromosomes Cancer. 2020 Feb;59(2):106-110. doi: 10.1002/gcc.22795. Epub 2019 Sep 3. PubMed PMID: 31390105.

40. Weinberg F, Griffin R, Fröhlich M, Heining C, Braun S, Spohr C, Iconomou M, Hollek V, Röring M, Horak P, Kreutzfeldt S, Warsow G, Hutter B, Uhrig S, Neumann O, Reuss D, Heiland DH, von Kalle C, Weichert W, Stenzinger A, Brors B, Glimm H, Fröhling S, Brummer T. Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. Oncogene. 2020 Jan;39(4):814-832. doi: 10.1038/s41388-019-1021-1. Epub 2019 Sep 26. PubMed PMID: 31558800.

1. Sondermann W, Utikal JS, Enk AH, Schadendorf D, Klode J, Hauschild A, Weichenthal M, French LE, Berking C, Schilling B, Haferkamp S, Fröhling S, von Kalle C, Brinker TJ. Corrigendum to 'Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data' [Eur J Cancer, 119 (September 2019) Pages 30-34]. Eur J Cancer. 2019 Dec;123:171. doi: 10.1016/j.ejca.2019.10.003. Epub 2019 Nov 7. PubMed PMID: 31708276.

2. Leichsenring J, Horak P, Kreutzfeldt S, Heining C, Christopoulos P, Volckmar AL, Neumann O, Kirchner M, Ploeger C, Budczies J, Heilig CE, Hutter B, Fröhlich M, Uhrig S, Kazdal D, Allgäuer M, Harms A, Rempel E, Lehmann U, Thomas M, Pfarr N, Azoitei N, Bonzheim I, Marienfeld R, Möller P, Werner M, Fend F, Boerries M, von Bubnoff N, Lassmann S, Longerich T, Bitzer M, Seufferlein T, Malek N, Weichert W, Schirmacher P, Penzel R, Endris V, Brors B, Klauschen F, Glimm H, Fröhling S, Stenzinger A. Variant classification in precision oncology. Int J Cancer. 2019 Dec 1;145(11):2996-3010. doi: 10.1002/ijc.32358. Epub 2019 May 21. PubMed PMID: 31008532.

3. Mock A, Heilig CE, Kreutzfeldt S, Huebschmann D, Heining C, Schröck E, Brors B, Stenzinger A, Jäger D, Schlenk R, Glimm H, Fröhling S, Horak P. Community-driven development of a modified progression-free survival ratio for precision oncology. ESMO Open. 2019;4(6):e000583. doi: 10.1136/esmoopen-2019-000583. eCollection 2019. PubMed PMID: 31798980; PubMed Central PMCID: PMC6863673.

4. Kazdal D, Endris V, Allgäuer M, Kriegsmann M, Leichsenring J, Volckmar AL, Harms A, Kirchner M, Kriegsmann K, Neumann O, Brandt R, Talla SB, Rempel E, Ploeger C, von Winterfeld M, Christopoulos P, Merino DM, Stewart M, Allen J, Bischoff H, Meister M, Muley T, Herth F, Penzel R, Warth A, Winter H, Fröhling S, Peters S, Swanton C, Thomas M, Schirmacher P, Budczies J, Stenzinger A. Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. J Thorac Oncol. 2019 Nov;14(11):1935-1947. doi: 10.1016/j.jtho.2019.07.006. Epub 2019 Jul 23. PubMed PMID: 31349062.

5. Mühlenberg T, Ketzer J, Heinrich MC, Grunewald S, Marino-Enriquez A, Trautmann M, Hartmann W, Wardelmann E, Treckmann J, Worm K, Bertram S, Herold T, Schildhaus HU, Glimm H, Stenzinger A, Brors B, Horak P, Hohenberger P, Fröhling S, Fletcher JA, Bauer S. KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy. Mol Cancer Ther. 2019 Nov;18(11):1985-1996. doi: 10.1158/1535-7163.MCT-18-1224. Epub 2019 Jul 15. PubMed PMID: 31308077.

6. Hekler A, Utikal JS, Enk AH, Hauschild A, Weichenthal M, Maron RC, Berking C, Haferkamp S, Klode J, Schadendorf D, Schilling B, Holland-Letz T, Izar B, von Kalle C, Fröhling S, Brinker TJ. Superior skin cancer classification by the combination of human and artificial intelligence. Eur J Cancer. 2019 Oct;120:114-121. doi: 10.1016/j.ejca.2019.07.019. Epub 2019 Sep 10. PubMed PMID: 31518967.

7. Maron RC, Weichenthal M, Utikal JS, Hekler A, Berking C, Hauschild A, Enk AH, Haferkamp S, Klode J, Schadendorf D, Jansen P, Holland-Letz T, Schilling B, von Kalle C, Fröhling S, Gaiser MR, Hartmann D, Gesierich A, Kähler KC, Wehkamp U, Karoglan A, Bär C, Brinker TJ. Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks. Eur J Cancer. 2019 Sep;119:57-65. doi: 10.1016/j.ejca.2019.06.013. Epub 2019 Aug 14. PubMed PMID: 31419752.

8. Sondermann W, Utikal JS, Enk AH, Schadendorf D, Klode J, Hauschild A, Weichenthal M, French LE, Berking C, Schilling B, Haferkamp S, Fröhling S, von Kalle C, Brinker TJ. Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data. Eur J Cancer. 2019 Sep;119:30-34. doi: 10.1016/j.ejca.2019.07.009. Epub 2019 Aug 8. PubMed PMID: 31401471.

9. Brinker TJ, Hekler A, Enk AH, Berking C, Haferkamp S, Hauschild A, Weichenthal M, Klode J, Schadendorf D, Holland-Letz T, von Kalle C, Fröhling S, Schilling B, Utikal JS. Deep neural networks are superior to dermatologists in melanoma image classification. Eur J Cancer. 2019 Sep;119:11-17. doi: 10.1016/j.ejca.2019.05.023. Epub 2019 Aug 8. PubMed PMID: 31401469.

10. Hekler A, Utikal JS, Enk AH, Solass W, Schmitt M, Klode J, Schadendorf D, Sondermann W, Franklin C, Bestvater F, Flaig MJ, Krahl D, von Kalle C, Fröhling S, Brinker TJ. Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images. Eur J Cancer. 2019 Sep;118:91-96. doi: 10.1016/j.ejca.2019.06.012. Epub 2019 Jul 18. PubMed PMID: 31325876.

11. Budczies J, Allgäuer M, Litchfield K, Rempel E, Christopoulos P, Kazdal D, Endris V, Thomas M, Fröhling S, Peters S, Swanton C, Schirmacher P, Stenzinger A. Optimizing panel-based tumor mutational burden (TMB) measurement. Ann Oncol. 2019 Sep 1;30(9):1496-1506. doi: 10.1093/annonc/mdz205. PubMed PMID: 31268125.

12. Volckmar AL, Leichsenring J, Kirchner M, Christopoulos P, Neumann O, Budczies J, Morais de Oliveira CM, Rempel E, Buchhalter I, Brandt R, Allgäuer M, Talla SB, von Winterfeld M, Herpel E, Goeppert B, Lier A, Winter H, Brummer T, Fröhling S, Faehling M, Fischer JR, Heußel CP, Herth F, Lasitschka F, Schirmacher P, Thomas M, Endris V, Penzel R, Stenzinger A. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. Int J Cancer. 2019 Aug 1;145(3):649-661. doi: 10.1002/ijc.32133. Epub 2019 Feb 19. PubMed PMID: 30653256.

13. Hekler A, Utikal JS, Enk AH, Berking C, Klode J, Schadendorf D, Jansen P, Franklin C, Holland-Letz T, Krahl D, von Kalle C, Fröhling S, Brinker TJ. Pathologist-level classification of histopathological melanoma images with deep neural networks. Eur J Cancer. 2019 Jul;115:79-83. doi: 10.1016/j.ejca.2019.04.021. Epub 2019 May 23. PubMed PMID: 31129383.

14. Longerich T, Endris V, Neumann O, Rempel E, Kirchner M, Abadi Z, Uhrig S, Kriegsmann M, Weiss KH, Breuhahn K, Mehrabi A, Weber TF, Wilkens L, Straub BK, Rosenwald A, Schulze F, Brors B, Froehling S, Pellegrino R, Budczies J, Schirmacher P, Stenzinger A. RSPO2 gene rearrangement: a powerful driver of β-catenin activation in liver tumours. Gut. 2019 Jul;68(7):1287-1296. doi: 10.1136/gutjnl-2018-317632. Epub 2019 Feb 2. PubMed PMID: 30901310.

15. Feuerbach L, Sieverling L, Deeg KI, Ginsbach P, Hutter B, Buchhalter I, Northcott PA, Mughal SS, Chudasama P, Glimm H, Scholl C, Lichter P, Fröhling S, Pfister SM, Jones DTW, Rippe K, Brors B. TelomereHunter - in silico estimation of telomere content and composition from cancer genomes. BMC Bioinformatics. 2019 May 28;20(1):272. doi: 10.1186/s12859-019-2851-0. PubMed PMID: 31138115; PubMed Central PMCID: PMC6540518.

16. Leichsenring J, Kazdal D, Ploeger C, Allgäuer M, Endris V, Volckmar AL, Neumann O, Kirchner M, Penzel R, Rempel E, Budczies J, Schirmacher P, Fröhling S, Stenzinger A. [From panel diagnostics to comprehensive genomic analysis : Infobesity or empowerment?]. Pathologe. 2019 May;40(3):235-242. doi: 10.1007/s00292-019-0608-1. PubMed PMID: 31089797.

17. Trautmann M, Cheng YY, Jensen P, Azoitei N, Brunner I, Hüllein J, Slabicki M, Isfort I, Cyra M, Berthold R, Wardelmann E, Huss S, Altvater B, Rossig C, Hafner S, Simmet T, Ståhlberg A, Åman P, Zenz T, Lange U, Kindler T, Scholl C, Hartmann W, Fröhling S. Requirement for YAP1 signaling in myxoid liposarcoma. EMBO Mol Med. 2019 May;11(5). doi: 10.15252/emmm.201809889. PubMed PMID: 30898787; PubMed Central PMCID: PMC6505681.

18. Endris V, Buchhalter I, Allgäuer M, Rempel E, Lier A, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, Neumann O, Penzel R, Weichert W, Glimm H, Fröhling S, Winter H, Herth F, Thomas M, Schirmacher P, Budczies J, Stenzinger A. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels. Int J Cancer. 2019 May 1;144(9):2303-2312. doi: 10.1002/ijc.32002. Epub 2019 Feb 4. PubMed PMID: 30446996.

19. Brinker TJ, Buslaff F, Suhre JL, Silchmüller MP, Divizieva E, Wilhelm J, Hillebrand G, Penka D, Gaim B, Swoboda S, Baumermann S, Walther JW, Brieske CM, Jakob L, Baumert HM, Anhuef O, Schmidt SM, Alfitian J, Batra A, Taha L, Mons U, Hofmann FJ, Haney AC, Haney CM, Schaible S, Tran TA, Beißwenger H, Stark T, Groneberg DA, Seeger W, Srivastava A, Gall H, Holzapfel J, Rigotti NA, Baudson TG, Enk AH, Fröhling S, von Kalle C, Bernardes-Souza B, Pereira RMOS, Thomas R. Process Evaluation of a Medical Student-Delivered Smoking Prevention Program for Secondary Schools: Protocol for the Education Against Tobacco Cluster Randomized Trial. JMIR Res Protoc. 2019 Apr 11;8(4):e13508. doi: 10.2196/13508. PubMed PMID: 30973348; PubMed Central PMCID: PMC6482400.

20. Gröschel S, Hübschmann D, Raimondi F, Horak P, Warsow G, Fröhlich M, Klink B, Gieldon L, Hutter B, Kleinheinz K, Bonekamp D, Marschal O, Chudasama P, Mika J, Groth M, Uhrig S, Krämer S, Heining C, Heilig CE, Richter D, Reisinger E, Pfütze K, Eils R, Wolf S, von Kalle C, Brandts C, Scholl C, Weichert W, Richter S, Bauer S, Penzel R, Schröck E, Stenzinger A, Schlenk RF, Brors B, Russell RB, Glimm H, Schlesner M, Fröhling S. Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. Nat Commun. 2019 Apr 9;10(1):1635. doi: 10.1038/s41467-019-09633-9. PubMed PMID: 30967556; PubMed Central PMCID: PMC6456501.

21. Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Fröhling S, Utikal JS, von Kalle C. A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. Eur J Cancer. 2019 Apr;111:148-154. doi: 10.1016/j.ejca.2019.02.005. Epub 2019 Mar 8. PubMed PMID: 30852421.

22. Horak P, Weischenfeldt J, von Amsberg G, Beyer B, Schütte A, Uhrig S, Gieldon L, Klink B, Feuerbach L, Hübschmann D, Kreutzfeldt S, Heining C, Maier S, Hutter B, Penzel R, Schlesner M, Eils R, Sauter G, Stenzinger A, Brors B, Schröck E, Glimm H, Fröhling S, Schlomm T. Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance. Cold Spring Harb Mol Case Stud. 2019 Apr;5(2). doi: 10.1101/mcs.a003657. Print 2019 Apr. PubMed PMID: 30833416; PubMed Central PMCID: PMC6549578.

23. Scholl C, Fröhling S. Exploiting rare driver mutations for precision cancer medicine. Curr Opin Genet Dev. 2019 Feb;54:1-6. doi: 10.1016/j.gde.2019.02.004. Epub 2019 Mar 4. Review. PubMed PMID: 30844512.

24. Buchhalter I, Rempel E, Endris V, Allgäuer M, Neumann O, Volckmar AL, Kirchner M, Leichsenring J, Lier A, von Winterfeld M, Penzel R, Christopoulos P, Thomas M, Fröhling S, Schirmacher P, Budczies J, Stenzinger A. Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. Int J Cancer. 2019 Feb 15;144(4):848-858. doi: 10.1002/ijc.31878. Epub 2018 Dec 4. PubMed PMID: 30238975.

25. Tapia-Laliena MÁ, Korzeniewski N, Peña-Llopis S, Scholl C, Fröhling S, Hohenfellner M, Duensing A, Duensing S. Cullin 5 is a novel candidate tumor suppressor in renal cell carcinoma involved in the maintenance of genome stability. Oncogenesis. 2019 Jan 9;8(1):4. doi: 10.1038/s41389-018-0110-2. PubMed PMID: 30631037; PubMed Central PMCID: PMC6328621.

1. Allgäuer M, Budczies J, Christopoulos P, Endris V, Lier A, Rempel E, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, Neumann O, Fröhling S, Penzel R, Thomas M, Schirmacher P, Stenzinger A. Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians. Transl Lung Cancer Res. 2018 Dec;7(6):703-715. doi: 10.21037/tlcr.2018.08.14. Review. PubMed PMID: 30505715; PubMed Central PMCID: PMC6249620.

2. Leichsenring J, Stögbauer F, Volckmar AL, Buchhalter I, Oliveira C, Kirchner M, Fröhling S, Hassel J, Enk A, Schirmacher P, Endris V, Penzel R, Stenzinger A. Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. Pathology. 2018 Dec;50(7):703-710. doi: 10.1016/j.pathol.2018.08.004. Epub 2018 Oct 20. PubMed PMID: 30348504.

3. Brien GL, Remillard D, Shi J, Hemming ML, Chabon J, Wynne K, Dillon ET, Cagney G, Van Mierlo G, Baltissen MP, Vermeulen M, Qi J, Fröhling S, Gray NS, Bradner JE, Vakoc CR, Armstrong SA. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife. 2018 Nov 15;7. doi: 10.7554/eLife.41305. PubMed PMID: 30431433; PubMed Central PMCID: PMC6277197.

4. Lier A, Penzel R, Heining C, Horak P, Fröhlich M, Uhrig S, Budczies J, Kirchner M, Volckmar AL, Hutter B, Kreutzfeldt S, Endris V, Richter D, Wolf S, Pfütze K, Neumann O, Buchhalter I, Morais de Oliveira CM, Singer S, Leichsenring J, Herpel E, Klauschen F, Jost PJ, Metzeler KH, Schulze-Osthoff K, Kopp HG, Kindler T, Rieke DT, Lamping M, Brandts C, Falkenhorst J, Bauer S, Schröck E, Folprecht G, Boerries M, von Bubnoff N, Weichert W, Brors B, Lichter P, von Kalle C, Schirmacher P, Glimm H, Fröhling S, Stenzinger A. Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience. JCO Precis Oncol. 2018 Nov;2:1-13. doi: 10.1200/PO.18.00171. PubMed PMID: 35135162.

5. Sanders MA, Chew E, Flensburg C, Zeilemaker A, Miller SE, Al Hinai AS, Bajel A, Luiken B, Rijken M, Mclennan T, Hoogenboezem RM, Kavelaars FG, Fröhling S, Blewitt ME, Bindels EM, Alexander WS, Löwenberg B, Roberts AW, Valk PJM, Majewski IJ. MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML. Blood. 2018 Oct 4;132(14):1526-1534. doi: 10.1182/blood-2018-05-852566. Epub 2018 Jul 26. PubMed PMID: 30049810; PubMed Central PMCID: PMC6172562.

6. Rudat S, Pfaus A, Cheng YY, Holtmann J, Ellegast JM, Bühler C, Marcantonio DD, Martinez E, Göllner S, Wickenhauser C, Müller-Tidow C, Lutz C, Bullinger L, Milsom MD, Sykes SM, Fröhling S, Scholl C. RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia. Leukemia. 2018 Oct;32(10):2189-2202. doi: 10.1038/s41375-018-0102-4. Epub 2018 Mar 22. PubMed PMID: 29654265.

7. Heining C, Horak P, Uhrig S, Codo PL, Klink B, Hutter B, Fröhlich M, Bonekamp D, Richter D, Steiger K, Penzel R, Endris V, Ehrenberg KR, Frank S, Kleinheinz K, Toprak UH, Schlesner M, Mandal R, Schulz L, Lambertz H, Fetscher S, Bitzer M, Malek NP, Horger M, Giese NA, Strobel O, Hackert T, Springfeld C, Feuerbach L, Bergmann F, Schröck E, von Kalle C, Weichert W, Scholl C, Ball CR, Stenzinger A, Brors B, Fröhling S, Glimm H. NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Cancer Discov. 2018 Sep;8(9):1087-1095. doi: 10.1158/2159-8290.CD-18-0036. Epub 2018 May 25. PubMed PMID: 29802158.

8. Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A. Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDH^mut-like DNA hypermethylation. Nature. 2018 Aug;560(7718):E28. doi: 10.1038/s41586-018-0403-9. PubMed PMID: 30069041.

9. Koelsche C, Hartmann W, Schrimpf D, Stichel D, Jabar S, Ranft A, Reuss DE, Sahm F, Jones DTW, Bewerunge-Hudler M, Trautmann M, Klingebiel T, Vokuhl C, Gessler M, Wardelmann E, Petersen I, Baumhoer D, Flucke U, Antonescu C, Esteller M, Fröhling S, Kool M, Pfister SM, Mechtersheimer G, Dirksen U, von Deimling A. Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information. Mod Pathol. 2018 Aug;31(8):1246-1256. doi: 10.1038/s41379-018-0045-3. Epub 2018 Mar 23. PubMed PMID: 29572501; PubMed Central PMCID: PMC7484949.

10. Terziev D, Hutter B, Klink B, Stenzinger A, Stögbauer F, Glimm H, Fröhling S, Wickenhauser C, Jordan K, Hurtz HJ, Müller LP, Rüssel J, Weber T. Nivolumab maintenance after salvage autologous stem cell transplantation results in long-term remission in multiple relapsed primary CNS lymphoma. Eur J Haematol. 2018 Jul;101(1):115-118. doi: 10.1111/ejh.13072. Epub 2018 May 11. PubMed PMID: 29624748.

11. Vogl T, Stratis A, Wixler V, Völler T, Thurainayagam S, Jorch SK, Zenker S, Dreiling A, Chakraborty D, Fröhling M, Paruzel P, Wehmeyer C, Hermann S, Papantonopoulou O, Geyer C, Loser K, Schäfers M, Ludwig S, Stoll M, Leanderson T, Schultze JL, König S, Pap T, Roth J. Autoinhibitory regulation of S100A8/S100A9 alarmin activity locally restricts sterile inflammation. J Clin Invest. 2018 May 1;128(5):1852-1866. doi: 10.1172/JCI89867. Epub 2018 Apr 3. PubMed PMID: 29611822; PubMed Central PMCID: PMC5919817.

12. Perera-Bel J, Hutter B, Heining C, Bleckmann A, Fröhlich M, Fröhling S, Glimm H, Brors B, Beißbarth T. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards. Genome Med. 2018 Mar 15;10(1):18. doi: 10.1186/s13073-018-0529-2. PubMed PMID: 29544535; PubMed Central PMCID: PMC5856211.

13. Di Marcantonio D, Martinez E, Sidoli S, Vadaketh J, Nieborowska-Skorska M, Gupta A, Meadows JM, Ferraro F, Masselli E, Challen GA, Milsom MD, Scholl C, Fröhling S, Balachandran S, Skorski T, Garcia BA, Mirandola P, Gobbi G, Garzon R, Vitale M, Sykes SM. Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clin Cancer Res. 2018 Feb 1;24(3):608-618. doi: 10.1158/1078-0432.CCR-17-2684. Epub 2017 Nov 10. PubMed PMID: 29127121; PubMed Central PMCID: PMC5796864.

14. Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, Wong SH, Rabe S, Hlevnjak M, Zapatka M, Ernst A, Kleinheinz K, Schlesner M, Sieverling L, Klink B, Schröck E, Hoogenboezem RM, Kasper B, Heilig CE, Egerer G, Wolf S, von Kalle C, Eils R, Stenzinger A, Weichert W, Glimm H, Gröschel S, Kopp HG, Omlor G, Lehner B, Bauer S, Schimmack S, Ulrich A, Mechtersheimer G, Rippe K, Brors B, Hutter B, Renner M, Hohenberger P, Scholl C, Fröhling S. Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun. 2018 Jan 10;9(1):144. doi: 10.1038/s41467-017-02602-0. PubMed PMID: 29321523; PubMed Central PMCID: PMC5762758.

15. Martins LR, Bung RK, Koch S, Richter K, Schwarzmüller L, Terhardt D, Kurtulmus B, Niehrs C, Rouhi A, Lohmann I, Pereira G, Fröhling S, Glimm H, Scholl C. Stk33 is required for spermatid differentiation and male fertility in mice. Dev Biol. 2018 Jan 1;433(1):84-93. doi: 10.1016/j.ydbio.2017.11.007. Epub 2017 Nov 16. PubMed PMID: 29155043.

1. Fröhling S. Many Roads Lead to snoRNAs: The Ever-Expanding Universe of Non-Coding RNAs in Acute Myeloid Leukemia. Hemasphere. 2017 Dec;1(1):e14. doi: 10.1097/HS9.0000000000000014. eCollection 2017 Dec. PubMed PMID: 31723743; PubMed Central PMCID: PMC6745981.

2. Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature. 2017 Nov 16;551(7680):384-388. doi: 10.1038/nature24294. Epub 2017 Nov 8. PubMed PMID: 29144447.

3. Forschner A, Niessner H, Möller Y, Horak P, Fröhlich M, Warsow G, Stenzinger A, Fröhling S, Glimm H, Klumpp B, Garbe C, Sinnberg T. Genomics of Immunotherapy-Associated Hyperprogressors-Letter. Clin Cancer Res. 2017 Oct 15;23(20):6374-6375. doi: 10.1158/1078-0432.CCR-17-1480. PubMed PMID: 29030332.

4. Trautmann M, Menzel J, Bertling C, Cyra M, Isfort I, Steinestel K, Elges S, Grünewald I, Altvater B, Rossig C, Fröhling S, Hafner S, Simmet T, Åman P, Wardelmann E, Huss S, Hartmann W. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma. Clin Cancer Res. 2017 Oct 15;23(20):6227-6238. doi: 10.1158/1078-0432.CCR-17-0130. Epub 2017 Jun 21. PubMed PMID: 28637688.

5. Heining C, Horak P, Gröschel S, Glimm H, Fröhling S. [Personalized oncology]. Radiologe. 2017 Oct;57(10):804-811. doi: 10.1007/s00117-017-0297-9. Review. PubMed PMID: 28875369.

6. Ugurel S, Kiecker F, Fröhling S, Wetter A, Bankfalvi A, Sucker A, Zimmer L, Livingstone E, Roesch A, Becker JC, Schadendorf D. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma. Eur J Cancer. 2017 Sep;83:142-145. doi: 10.1016/j.ejca.2017.06.020. Epub 2017 Jul 20. PubMed PMID: 28735071.

7. Czink E, Kloor M, Goeppert B, Fröhling S, Uhrig S, Weber TF, Meinel J, Sutter C, Weiss KH, Schirmacher P, Doeberitz MVK, Jäger D, Springfeld C. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. Cold Spring Harb Mol Case Stud. 2017 Sep;3(5). doi: 10.1101/mcs.a001974. Print 2017 Sep. PubMed PMID: 28619747; PubMed Central PMCID: PMC5593153.

8. Horak P, Klink B, Heining C, Gröschel S, Hutter B, Fröhlich M, Uhrig S, Hübschmann D, Schlesner M, Eils R, Richter D, Pfütze K, Geörg C, Meißburger B, Wolf S, Schulz A, Penzel R, Herpel E, Kirchner M, Lier A, Endris V, Singer S, Schirmacher P, Weichert W, Stenzinger A, Schlenk RF, Schröck E, Brors B, von Kalle C, Glimm H, Fröhling S. Precision oncology based on omics data: The NCT Heidelberg experience. Int J Cancer. 2017 Sep 1;141(5):877-886. doi: 10.1002/ijc.30828. Epub 2017 Jun 21. PubMed PMID: 28597939.

9. Budczies J, Bockmayr M, Klauschen F, Endris V, Fröhling S, Schirmacher P, Denkert C, Stenzinger A. Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors. Genes Chromosomes Cancer. 2017 Aug;56(8):651-659. doi: 10.1002/gcc.22468. Epub 2017 May 31. PubMed PMID: 28466543.

10. Giessler KM, Kleinheinz K, Huebschmann D, Balasubramanian GP, Dubash TD, Dieter SM, Siegl C, Herbst F, Weber S, Hoffmann CM, Fronza R, Buchhalter I, Paramasivam N, Eils R, Schmidt M, von Kalle C, Schneider M, Ulrich A, Scholl C, Fröhling S, Weichert W, Brors B, Schlesner M, Ball CR, Glimm H. Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer. J Exp Med. 2017 Jul 3;214(7):2073-2088. doi: 10.1084/jem.20162017. Epub 2017 Jun 1. PubMed PMID: 28572216; PubMed Central PMCID: PMC5502434.

11. Ball CR, Oppel F, Ehrenberg KR, Dubash TD, Dieter SM, Hoffmann CM, Abel U, Herbst F, Koch M, Werner J, Bergmann F, Ishaque N, Schmidt M, von Kalle C, Scholl C, Fröhling S, Brors B, Weichert W, Weitz J, Glimm H. Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts. EMBO Mol Med. 2017 Jul;9(7):918-932. doi: 10.15252/emmm.201607354. PubMed PMID: 28526679; PubMed Central PMCID: PMC5494525.

12. Zhou C, Martinez E, Di Marcantonio D, Solanki-Patel N, Aghayev T, Peri S, Ferraro F, Skorski T, Scholl C, Fröhling S, Balachandran S, Wiest DL, Sykes SM. JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia. Leukemia. 2017 May;31(5):1196-1205. doi: 10.1038/leu.2016.329. Epub 2016 Nov 14. PubMed PMID: 27840425; PubMed Central PMCID: PMC5473421.

13. Hernandez Maganhi S, Jensen P, Caracelli I, Zukerman Schpector J, Fröhling S, Friedman R. Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein. Protein Sci. 2017 Apr;26(4):870-879. doi: 10.1002/pro.3135. Epub 2017 Mar 6. PubMed PMID: 28168755; PubMed Central PMCID: PMC5368058.

14. Chudasama P, Renner M, Straub M, Mughal SS, Hutter B, Kosaloglu Z, Schweßinger R, Scheffler M, Alldinger I, Schimmack S, Persigehl T, Kobe C, Jäger D, von Kalle C, Schirmacher P, Beckhaus MK, Wolf S, Heining C, Gröschel S, Wolf J, Brors B, Weichert W, Glimm H, Scholl C, Mechtersheimer G, Specht K, Fröhling S. Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma. Clin Cancer Res. 2017 Feb 15;23(4):962-973. doi: 10.1158/1078-0432.CCR-16-0860. Epub 2016 Aug 17. PubMed PMID: 27535980.

15. Winkler JK, Schneiderbauer R, Bender C, Sedlaczek O, Fröhling S, Penzel R, Enk A, Hassel JC. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. Br J Dermatol. 2017 Feb;176(2):498-502. doi: 10.1111/bjd.14664. Epub 2016 Oct 17. PubMed PMID: 27061826.

16. Rouhi A, Miller C, Grasedieck S, Reinhart S, Stolze B, Döhner H, Kuchenbauer F, Bullinger L, Fröhling S, Scholl C. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells. Oncotarget. 2017 Jan 31;8(5):7678-7690. doi: 10.18632/oncotarget.13841. PubMed PMID: 28032595; PubMed Central PMCID: PMC5352352.

17. Budczies J, Mechtersheimer G, Denkert C, Klauschen F, Mughal SS, Chudasama P, Bockmayr M, Jöhrens K, Endris V, Lier A, Lasitschka F, Penzel R, Dietel M, Brors B, Gröschel S, Glimm H, Schirmacher P, Renner M, Fröhling S, Stenzinger A. PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. Oncoimmunology. 2017;6(3):e1279777. doi: 10.1080/2162402X.2017.1279777. eCollection 2017. PubMed PMID: 28405504; PubMed Central PMCID: PMC5384369.

18. Dieter SM, Heining C, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg KR, Fröhlich M, Schlesner M, Scholl C, Schlemmer HP, Wolf S, Mavratzas A, Jung CS, Gröschel S, von Kalle C, Eils R, Brors B, Penzel R, Kriegsmann M, Reuss DE, Schirmacher P, Stenzinger A, Federspil PA, Weichert W, Glimm H, Fröhling S. Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma. Ann Oncol. 2017 Jan 1;28(1):142-148. doi: 10.1093/annonc/mdw446. PubMed PMID: 27687311.

1. Słabicki M, Lee KS, Jethwa A, Sellner L, Sacco F, Walther T, Hüllein J, Dietrich S, Wu B, Lipka DB, Oakes CC, Mamidi S, Pyrzyńska B, Winiarska M, Oleś M, Seifert M, Plass C, Kirschfink M, Boettcher M, Gołąb J, Huber W, Fröhling S, Zenz T. Dissection of CD20 regulation in lymphoma using RNAi. Leukemia. 2016 Dec;30(12):2409-2412. doi: 10.1038/leu.2016.230. Epub 2016 Aug 18. PubMed PMID: 27560109.

2. Horak P, Fröhling S, Glimm H. Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open. 2016;1(5):e000094. doi: 10.1136/esmoopen-2016-000094. eCollection 2016. Review. PubMed PMID: 27933214; PubMed Central PMCID: PMC5133384.

3. Gröschel S, Bommer M, Hutter B, Budczies J, Bonekamp D, Heining C, Horak P, Fröhlich M, Uhrig S, Hübschmann D, Geörg C, Richter D, Pfarr N, Pfütze K, Wolf S, Schirmacher P, Jäger D, von Kalle C, Brors B, Glimm H, Weichert W, Stenzinger A, Fröhling S. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. Cold Spring Harb Mol Case Stud. 2016 Nov;2(6):a001180. doi: 10.1101/mcs.a001180. PubMed PMID: 27900363; PubMed Central PMCID: PMC5111004.

4. Bochtler T, Fröhling S, Weichert W, Endris V, Thiede C, Hutter B, Hundemer M, Ho AD, Krämer A. Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia. Cold Spring Harb Mol Case Stud. 2016 Sep;2(5):a001123. doi: 10.1101/mcs.a001123. PubMed PMID: 27626069; PubMed Central PMCID: PMC5002926.

5. Budczies J, Bockmayr M, Denkert C, Klauschen F, Gröschel S, Darb-Esfahani S, Pfarr N, Leichsenring J, Onozato ML, Lennerz JK, Dietel M, Fröhling S, Schirmacher P, Iafrate AJ, Weichert W, Stenzinger A. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival. Genes Chromosomes Cancer. 2016 Aug;55(8):626-39. doi: 10.1002/gcc.22365. Epub 2016 May 30. PubMed PMID: 27106868.

6. Uras IZ, Walter GJ, Scheicher R, Bellutti F, Prchal-Murphy M, Tigan AS, Valent P, Heidel FH, Kubicek S, Scholl C, Fröhling S, Sexl V. Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood. 2016 Jun 9;127(23):2890-902. doi: 10.1182/blood-2015-11-683581. Epub 2016 Apr 20. PubMed PMID: 27099147; PubMed Central PMCID: PMC4920675.

7. Czink E, Heining C, Weber TF, Lasitschka F, Schemmer P, Schirmacher P, Weiss KH, Glimm H, Brors B, Weichert W, Jäger D, Fröhling S, Springfeld C. [Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer]. Z Gastroenterol. 2016 May;54(5):426-30. doi: 10.1055/s-0042-103498. Epub 2016 May 12. PubMed PMID: 27171333.

8. Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H, Brummer T, Fröhling S. Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia. 2016 Apr;30(4):937-46. doi: 10.1038/leu.2015.319. Epub 2015 Nov 19. PubMed PMID: 26582644.

9. Ronellenfitsch U, Dimitrakopoulou-Strauss A, Jakob J, Kasper B, Nowak K, Pilz LR, Attenberger U, Gaiser T, Egerer G, Fröhling S, Derigs HG, Schwarzbach M, Hohenberger P. Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS). BMJ Open. 2016 Jan 6;6(1):e009558. doi: 10.1136/bmjopen-2015-009558. PubMed PMID: 26739732; PubMed Central PMCID: PMC4716254.

1. Husedzinovic A, Ose D, Schickhardt C, Fröhling S, Winkler EC. Stakeholders' perspectives on biobank-based genomic research: systematic review of the literature. Eur J Hum Genet. 2015 Dec;23(12):1607-14. doi: 10.1038/ejhg.2015.27. Epub 2015 Mar 4. Review. PubMed PMID: 25735479; PubMed Central PMCID: PMC4795193.

2. Dietrich S, Hüllein J, Lee SC, Hutter B, Gonzalez D, Jayne S, Dyer MJ, Oleś M, Else M, Liu X, Słabicki M, Wu B, Troussard X, Dürig J, Andrulis M, Dearden C, von Kalle C, Granzow M, Jauch A, Fröhling S, Huber W, Meggendorfer M, Haferlach T, Ho AD, Richter D, Brors B, Glimm H, Matutes E, Abdel Wahab O, Zenz T. Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood. 2015 Aug 20;126(8):1005-8. doi: 10.1182/blood-2015-04-643361. Epub 2015 Jun 11. PubMed PMID: 26065650.

3. Kang HB, Fan J, Lin R, Elf S, Ji Q, Zhao L, Jin L, Seo JH, Shan C, Arbiser JL, Cohen C, Brat D, Miziorko HM, Kim E, Abdel-Wahab O, Merghoub T, Fröhling S, Scholl C, Tamayo P, Barbie DA, Zhou L, Pollack BP, Fisher K, Kudchadkar RR, Lawson DH, Sica G, Rossi M, Lonial S, Khoury HJ, Khuri FR, Lee BH, Boggon TJ, He C, Kang S, Chen J. Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Mol Cell. 2015 Aug 6;59(3):345-358. doi: 10.1016/j.molcel.2015.05.037. Epub 2015 Jul 2. PubMed PMID: 26145173; PubMed Central PMCID: PMC4530073.

4. Bochtler T, Fröhling S, Krämer A. Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia. Leukemia. 2015 Jun;29(6):1243-52. doi: 10.1038/leu.2015.32. Epub 2015 Feb 12. Review. PubMed PMID: 25673237.

5. Azoitei N, Fröhling S, Scholl C, Seufferlein T. PRKD2: A two-pronged kinase crucial for the tumor-supporting activity of HSP90. Mol Cell Oncol. 2015 Apr-Jun;2(2):e981444. doi: 10.4161/23723556.2014.981444. eCollection 2015 Apr-Jun. PubMed PMID: 27308444; PubMed Central PMCID: PMC4904966.

6. Sandhöfer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiß V, Carlet M, Walter G, Hinrichsen T, Wachter O, Grunert M, Schneider S, Subklewe M, Dufour A, Fröhling S, Klein HG, Hiddemann W, Jeremias I, Spiekermann K. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. Leukemia. 2015 Apr;29(4):828-38. doi: 10.1038/leu.2014.305. Epub 2014 Oct 17. PubMed PMID: 25322685.

7. Stolze B, Reinhart S, Bulllinger L, Fröhling S, Scholl C. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci Rep. 2015 Feb 23;5:8535. doi: 10.1038/srep08535. PubMed PMID: 25705018; PubMed Central PMCID: PMC4336936.

1. Azoitei N, Diepold K, Brunner C, Rouhi A, Genze F, Becher A, Kestler H, van Lint J, Chiosis G, Koren J 3rd, Fröhling S, Scholl C, Seufferlein T. HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization. Cancer Res. 2014 Dec 1;74(23):7125-36. doi: 10.1158/0008-5472.CAN-14-1017. Epub 2014 Oct 8. PubMed PMID: 25297628; PubMed Central PMCID: PMC4315623.

2. Yaktapour N, Meiss F, Mastroianni J, Zenz T, Andrlova H, Mathew NR, Claus R, Hutter B, Fröhling S, Brors B, Pfeifer D, Pantic M, Bartsch I, Spehl TS, Meyer PT, Duyster J, Zirlik K, Brummer T, Zeiser R. BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. J Clin Invest. 2014 Nov;124(11):5074-84. doi: 10.1172/JCI76539. Epub 2014 Oct 20. PubMed PMID: 25329694; PubMed Central PMCID: PMC4347247.

3. Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C, Fröhling S. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014 Jul 3;124(1):13-23. doi: 10.1182/blood-2014-02-558114. Epub 2014 Apr 24. PubMed PMID: 24764564; PubMed Central PMCID: PMC4190617.

1. Dietrich S, Hüllein J, Hundemer M, Lehners N, Jethwa A, Capper D, Acker T, Garvalov BK, Andrulis M, Blume C, Schulte C, Mandel T, Meissner J, Fröhling S, von Kalle C, Glimm H, Ho AD, Zenz T. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol. 2013 Jul 1;31(19):e300-3. doi: 10.1200/JCO.2012.45.9495. Epub 2013 May 20. PubMed PMID: 23690412.

2. Rouhi A, Fröhling S. Deregulation of the CDX2-KLF4 axis in acute myeloid leukemia and colon cancer. Oncotarget. 2013 Feb;4(2):174-5. doi: 10.18632/oncotarget.896. PubMed PMID: 23563447; PubMed Central PMCID: PMC3712560.

3. Rücker FG, Russ AC, Cocciardi S, Kett H, Schlenk RF, Botzenhardt U, Langer C, Krauter J, Fröhling S, Schlegelberger B, Ganser A, Lichter P, Zenz T, Döhner H, Döhner K, Bullinger L. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance. Leukemia. 2013 Feb;27(2):353-61. doi: 10.1038/leu.2012.208. Epub 2012 Jul 19. PubMed PMID: 22810507.

4. Faber K, Bullinger L, Ragu C, Garding A, Mertens D, Miller C, Martin D, Walcher D, Döhner K, Döhner H, Claus R, Plass C, Sykes SM, Lane SW, Scholl C, Fröhling S. CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling. J Clin Invest. 2013 Jan;123(1):299-314. doi: 10.1172/JCI64745. Epub 2012 Dec 3. PubMed PMID: 23202735; PubMed Central PMCID: PMC3533294.

1. Fröhling S. Widespread over-expression of the non-clustered homeobox gene HLX in acute myeloid leukemia. Haematologica. 2012 Oct;97(10):1453. doi: 10.3324/haematol.2012.076612. PubMed PMID: 23053668; PubMed Central PMCID: PMC3487543.

2. Fröhling S. Ligand-induced MET signaling as targetable codependence in acute myeloid leukemia. Haematologica. 2012 Aug;97(8):1118. doi: 10.3324/haematol.2012.073635. PubMed PMID: 22855844; PubMed Central PMCID: PMC3409806.

3. Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, Scholl C. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med. 2012 Apr 9;209(4):697-711. doi: 10.1084/jem.20111910. Epub 2012 Mar 26. PubMed PMID: 22451720; PubMed Central PMCID: PMC3328372.

4. Rücker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, Habdank M, Kugler CM, Holzmann K, Gaidzik VI, Paschka P, Held G, von Lilienfeld-Toal M, Lübbert M, Fröhling S, Zenz T, Krauter J, Schlegelberger B, Ganser A, Lichter P, Döhner K, Döhner H. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012 Mar 1;119(9):2114-21. doi: 10.1182/blood-2011-08-375758. Epub 2011 Dec 20. PubMed PMID: 22186996.

5. Luo T, Masson K, Jaffe JD, Silkworth W, Ross NT, Scherer CA, Scholl C, Fröhling S, Carr SA, Stern AM, Schreiber SL, Golub TR. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2860-5. doi: 10.1073/pnas.1120589109. Epub 2012 Feb 9. PubMed PMID: 22323609; PubMed Central PMCID: PMC3286931.

6. Bullinger L, Fröhling S. Array-based cytogenetic approaches in acute myeloid leukemia: clinical impact and biological insights. Semin Oncol. 2012 Feb;39(1):37-46. doi: 10.1053/j.seminoncol.2011.11.005. Review. PubMed PMID: 22289490.

7. Fröhling S, Scholl C. STK33 kinase is not essential in KRAS-dependent cells--letter. Cancer Res. 2011 Dec 15;71(24):7716; author reply 7717. doi: 10.1158/0008-5472.CAN-11-2495. Epub 2011 Nov 29. PubMed PMID: 22127923.

8. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Tothova Z, Attar EC, Fröhling S, DePinho RA, Armstrong SA, Gilliland DG, Scadden DT. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 2011 Sep 2;146(5):697-708. doi: 10.1016/j.cell.2011.07.032. PubMed PMID: 21884932; PubMed Central PMCID: PMC3826540.

9. Koo S, Huntly BJ, Wang Y, Chen J, Brumme K, Ball B, McKinney-Freeman SL, Yabuuchi A, Scholl C, Bansal D, Zon LI, Fröhling S, Daley GQ, Gilliland DG, Mercher T. Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis. Haematologica. 2010 Oct;95(10):1642-50. doi: 10.3324/haematol.2010.023168. Epub 2010 May 21. PubMed PMID: 20494928; PubMed Central PMCID: PMC2948088.

10. Corbacioglu A, Scholl C, Schlenk RF, Eiwen K, Du J, Bullinger L, Fröhling S, Reimer P, Rummel M, Derigs HG, Nachbaur D, Krauter J, Ganser A, Döhner H, Döhner K. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol. 2010 Aug 10;28(23):3724-9. doi: 10.1200/JCO.2010.28.6468. Epub 2010 Jul 12. PubMed PMID: 20625124.

11. Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, Morgan K, Tam W, Paktinat M, Okabe R, Gozo M, Einhorn W, Lane SW, Scholl C, Fröhling S, Fleming M, Ebert BL, Gilliland DG, Jaenisch R, Daley GQ. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010 Aug;16(8):903-8. doi: 10.1038/nm.2187. Epub 2010 Jul 8. PubMed PMID: 20616797; PubMed Central PMCID: PMC3090658.

12.  Zenz T, Fröhling S, Mertens D, Döhner H, Stilgenbauer S. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol. 2010 Mar;23(1):71-84. doi: 10.1016/j.beha.2009.12.003. Review. PubMed PMID: 20620972.

13. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009 Nov 5;462(7269):108-12. doi: 10.1038/nature08460. Epub 2009 Oct 21. PubMed PMID: 19847166; PubMed Central PMCID: PMC2783335.

14. Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Döhner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009 May 29;137(5):821-34. doi: 10.1016/j.cell.2009.03.017. PubMed PMID: 19490892; NIHMSID:NIHMS121220.

15. Schlenk RF, Döhner K, Kneba M, Götze K, Hartmann F, Del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, Habdank M, Späth D, Groner S, Krebs B, Kayser S, Corbacioglu A, Anhalt A, Benner A, Fröhling S, Döhner H. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica. 2009 Jan;94(1):54-60. doi: 10.3324/haematol.13378. Epub 2008 Dec 4. PubMed PMID: 19059939; PubMed Central PMCID: PMC2625424.

16. George RE, Sanda T, Hanna M, Fröhling S, Luther W 2nd, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008 Oct 16;455(7215):975-8. doi: 10.1038/nature07397. PubMed PMID: 18923525; PubMed Central PMCID: PMC2587486.